Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex

◆

Subtypes

3

ALS-predominant

Presentation dominated by upper- and lower-motor-neuron disease within the Guam ALS-PDC spectrum.

Show evidence (1 reference)

PMID:18843496 SUPPORT Human Clinical

"Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions involving multiple nerve fiber tracts occurred in both the ALS and PDC types, reinforcing the concept that these forms are part of the same disorder."

Human Guam autopsies identify ALS and PDC clinical-pathologic forms within one disorder.

Parkinsonism-dementia-predominant

Presentation dominated by rigido-akinetic parkinsonism and progressive dementia, with variable motor-neuron signs.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Important diagnostic indicators of the illness include rigido-akinetic type Parkinsonism and severe dementia."

The Guam clinical overview defines the core PDC presentation.

Mixed ALS-PDC

Presentation in which motor-neuron disease, parkinsonism, and dementia overlap clinically rather than segregating into a single predominant form.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"These mixed-syndrome patients can be seen as clear support for the view that Guam ALS and PDC constitute a single mixed disease entity with a spectrum of clinical expression."

The clinical review explicitly supports a mixed ALS-PDC spectrum.

◈

Mechanistic Hypotheses

2

Observed Guam Multiple-Proteinopathy and Regional Neurodegeneration

canonical_guam_multiple_proteinopathy CANONICAL ALS-predominant PDC-predominant Mixed ALS-PDC

Evidence balance 2 support

The default disease model is etiology-agnostic: observed tau-dominant neurofibrillary pathology and TDP-43 inclusions accompany degeneration of motor and nigrostriatal systems and neuronal pathology accompanying cognitive manifestations. Human studies establish the lesions and clinical spectrum but do not establish which protein lesion is primary or the direction of causation between them.

Pathograph links

Tau-Dominant Neurofibrillary Pathology -> Dementia-Associated Neuronal Dysfunction INDIRECT UNKNOWN INTERMEDIATES Neocortical tau pathology accompanies the dementia-bearing disease, but the human evidence does not resolve the causal intermediates or establish tau as the sole cause of cognitive decline.

Tau-Dominant Neurofibrillary Pathology -> Nigrostriatal Dopaminergic Dysfunction INDIRECT UNKNOWN INTERMEDIATES Tau pathology and presynaptic dopaminergic dysfunction coexist in the PDC form; a direct tau-to-nigrostriatal causal route has not been demonstrated.

TDP-43-Positive Cellular Inclusions -> Motor Neuron Degeneration INDIRECT UNKNOWN INTERMEDIATES TDP-43 inclusions occur in the ALS-bearing Guam disease, but human autopsy data do not establish a direct aggregation-to-motor-neuron-loss sequence.

Motor Neuron Degeneration -> Motor Neuron Disease (ALS) DIRECT Motor-system degeneration produces the ALS-predominant component of the disease spectrum.

Motor Neuron Degeneration -> Hyperreflexia INDIRECT KNOWN INTERMEDIATES Upper-motor-neuron and pyramidal-system dysfunction produces hyperactive stretch reflexes. Intermediates: Upper-motor-neuron and pyramidal-tract dysfunction

Motor Neuron Degeneration -> Distal Amyotrophy INDIRECT KNOWN INTERMEDIATES Lower-motor-neuron denervation produces distal spinal muscular atrophy. Intermediates: Lower-motor-neuron denervation and skeletal-muscle wasting

Nigrostriatal Dopaminergic Dysfunction -> Atypical Parkinsonism DIRECT Presynaptic nigrostriatal dopaminergic dysfunction produces the parkinsonian component.

Nigrostriatal Dopaminergic Dysfunction -> Rigidity INDIRECT KNOWN INTERMEDIATES Dopaminergic and extrapyramidal dysfunction contributes to marked rigidity. Intermediates: Striatal dopamine deficiency and extrapyramidal motor-circuit dysfunction

Nigrostriatal Dopaminergic Dysfunction -> Gait Disturbance INDIRECT KNOWN INTERMEDIATES Bradykinesia, rigidity, and impaired postural reflexes disrupt gait. Intermediates: Bradykinesia, rigidity, and impaired postural reflexes

Dementia-Associated Neuronal Dysfunction -> Dementia DIRECT Progressive neuronal dysfunction manifests clinically as dementia.

Show evidence (2 references)

PMID:18843496 SUPPORT Human Clinical

"Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions involving multiple nerve fiber tracts occurred in both the ALS and PDC types, reinforcing the concept that these forms are part of the same disorder."

Guam autopsy evidence supports the shared mixed-proteinopathy spectrum.

PMID:36952379 SUPPORT In Vitro

"In ALS-PDC brain samples, we detected high titers of tau and Aβ prions, but we did not detect α-synuclein prions in either cohort."

Cellular bioassays of human brain extracts establish tau and amyloid-beta prion activity while distinguishing it from alpha-synuclein prion activity.

Cycad-Derived L-BMAA Neurotoxicity Model

cycad_bmaa_neurotoxicity_model ALTERNATIVE

Evidence balance 1 support 1 refute

Chronic dietary L-BMAA exposure through traditional cycad-associated foods is proposed to cause glutamate-receptor-mediated motor-neuron injury and, based on a primate model, tau and amyloid-beta pathology. The mechanistic steps are experimentally supported in cells and vervets, but human Guam causation is not established and a critical review found the causal hypothesis unsupported.

Pathograph links

L-BMAA Neurotoxic Exposure -> AMPA/Kainate Receptor Overactivation and Calcium Overload DIRECT In spinal-cord cultures, BMAA activates AMPA/kainate receptors and preferentially raises motor-neuron intracellular calcium.

L-BMAA Neurotoxic Exposure -> Tau-Dominant Neurofibrillary Pathology INDIRECT UNKNOWN INTERMEDIATES Chronic dietary BMAA produced tau tangles in a vervet model; translation to human Guam disease remains unproven.

AMPA/Kainate Receptor Overactivation and Calcium Overload -> Oxidative Stress in Vulnerable Motor Neurons DIRECT BMAA-induced calcium stress accompanies selective ROS generation in cultured motor neurons.

AMPA/Kainate Receptor Overactivation and Calcium Overload -> Excitotoxic Motor Neuron Death DIRECT AMPA/kainate receptor activation is required for BMAA-induced death in cultured motor neurons.

Oxidative Stress in Vulnerable Motor Neurons -> Excitotoxic Motor Neuron Death INDIRECT KNOWN INTERMEDIATES Selective ROS generation accompanies BMAA-induced motor-neuron loss, but the experiment does not fully isolate ROS as the sole mediator. Intermediates: Oxidative injury and loss of cellular redox homeostasis

Excitotoxic Motor Neuron Death -> Motor Neuron Degeneration INDIRECT UNKNOWN INTERMEDIATES Experimental motor-neuron death is a possible route to the human motor-system lesion, but cross-system translation is unresolved.

Show evidence (2 references)

PMID:26791617 SUPPORT Model Organism

"In replicated experiments, we found that chronic dietary exposure to a cyanobacterial toxin present in the traditional Chamorro diet, β-N-methylamino-l-alanine (BMAA), triggers the formation of both NFT and β-amyloid deposits similar in structure and density to those found in brain tissues of..."

Vervet experiments support the model but cannot establish human Guam causation.

PMID:28598725 REFUTE Other

"The review concludes that the hypothesis of a causal BMAA neurodegenerative disease relationship is not supported by existing data."

A critical review directly challenges the human causal interpretation.

?

Discussions and Knowledge Gaps

4

What initiates Guam ALS-PDC, and how do genetic susceptibility and historical environmental change interact?

KNOWLEDGE GAP OPEN gap_guam_alspdc_etiology

Attached to

pathophysiology#Tau-Dominant Neurofibrillary Pathology pathophysiology#TDP-43-Positive Cellular Inclusions

Human studies establish a mixed proteinopathy and changing incidence, but no genetic variant, dietary toxin, mineral exposure, or other environmental factor has been shown to be necessary or sufficient. The rapid temporal change argues against a purely genetic cause without identifying the responsible exposure.

Show evidence (2 references)

PMID:36952379 SUPPORT Other

"Extensive studies of genetic or environmental factors have failed to identify a cause of ALS-PDC."

Directly states the unresolved etiologic gap.

PMID:12522022 SUPPORT Human Clinical

"The rapid decrease in incidence is not likely to be due to genetic factors."

Constrains a purely genetic explanation but does not identify an alternative cause.

Do BMAA, sterol glucosides, or another cycad constituent reproduce the initiating human exposure and mechanism of Guam ALS-PDC?

HUMAN MODEL MISMATCH OPEN gap_cycad_model_to_human_translation

Attached to

pathophysiology#L-BMAA Neurotoxic Exposure pathophysiology#AMPA/Kainate Receptor Overactivation and Calcium Overload

Mouse and vervet exposure models reproduce selected motor, cognitive, tau, amyloid, or motor-neuron readouts, but exposure identity and dose in affected people remain unresolved. The sterol-glucoside and L-BMAA models must not be collapsed into one exposure, and partial phenocopy does not demonstrate human causation.

Show evidence (2 references)

PMID:12095162 SUPPORT Model Organism

"These data are consistent with a number of major features of ALS-PDC in humans."

The authors claim consistency with selected features, not complete model fidelity.

PMID:28598725 REFUTE Other

"The review concludes that the hypothesis of a causal BMAA neurodegenerative disease relationship is not supported by existing data."

Directly records the gap between experimental BMAA findings and demonstrated human causation.

Which premortem biomarker combination can distinguish Guam ALS-PDC from overlapping neurodegenerative disorders?

KNOWLEDGE GAP OPEN gap_premortem_case_definition_and_biomarkers

Attached to

diagnosis#Postmortem Neuropathologic Examination

Clinical examination, ocular findings, retinal epitheliopathy, and fluorodopa PET are informative but individually nonspecific. No contemporary validated premortem case definition or biomarker panel was identified in the reviewed literature.

Show evidence (1 reference)

PMID:21527311 SUPPORT Other

"There are as yet no identified pathological features that will clearly distinguish the Guam or Kii ALS/PDC syndrome from other degenerative neurological disorders."

Directly supports the differential-diagnostic biomarker gap as assessed in 2011.

Which interventions alter progression or survival in Guam ALS-PDC rather than only treating symptoms?

KNOWLEDGE GAP OPEN gap_disease_modifying_treatment_and_trials

The retained literature supports only occasional early levodopa response. Searches of the disease literature and ClinicalTrials.gov through 2026-08-04 identified no Guam ALS-PDC-specific controlled therapeutic trial or established disease-modifying intervention. Trials in sporadic ALS, Parkinson disease, or progressive supranuclear palsy were not generalized to this complex.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"These cases occasionally present with the same clinical picture and response to levodopa in the early stage."

Documents limited symptomatic response evidence while leaving progression, survival, and disease modification untested.

⚙

Pathophysiology

9

Tau-Dominant Neurofibrillary Pathology

Widespread neuronal tau tangles are the dominant, consistently observed postmortem lesion in Guam ALS-PDC. Human bioassays also detect abundant tau prion activity. These observations establish the pathology but not its initiating cause or whether tau is the sole driver of regional neuronal loss.

Observed Guam Multiple-Proteinopathy and Regional Neurodegeneration

neuron CL:0000540

inclusion body assembly GO:0070841 ↑ INCREASED

Downstream

Dementia-Associated Neuronal Dysfunction Neocortical tau pathology accompanies the dementia-bearing disease, but the human evidence does not resolve the causal intermediates or establish tau as the sole cause of cognitive decline.

Nigrostriatal Dopaminergic Dysfunction Tau pathology and presynaptic dopaminergic dysfunction coexist in the PDC form; a direct tau-to-nigrostriatal causal route has not been demonstrated.

Show evidence (4 references)

PMID:36952379 SUPPORT Human Clinical

"The amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC) of Guam is an endemic neurodegenerative disease that features widespread tau tangles, occasional α-synuclein Lewy bodies, and sparse β-amyloid (Aβ) plaques distributed in the central nervous system."

Directly establishes widespread tau tangles in Guam ALS-PDC.

PMID:21527311 SUPPORT Other

"The most prominent pathological hallmark is the widespread occurrence of neurofibrillary tangles which express the same balance of 3R and 4R tau that is found in Alzheimer disease."

The Guam review identifies widespread mixed 3R/4R tangles as the principal pathologic hallmark.

PMID:38100415 SUPPORT In Vitro

"Here, we used electron cryo-microscopy to determine the structures of tau filaments from the cerebral cortex of three cases of ALS/PDC from Guam and eight cases from Kii, as well as from the spinal cord of two of the Guam cases. Tau filaments had the chronic traumatic encephalopathy (CTE) fold,..."

Establishes the filament fold in the three sampled Guam cortices and two sampled Guam spinal cords; it does not establish why that fold formed.

+ 1 more reference

TDP-43-Positive Cellular Inclusions

TDP-43-positive neuronal and glial inclusions occur in Guam ALS-PDC across both ALS and PDC forms. The available Guam evidence establishes inclusion-positive cells but does not specify cytoplasmic localization.

Observed Guam Multiple-Proteinopathy and Regional Neurodegeneration

neuron CL:0000540

Downstream

Motor Neuron Degeneration TDP-43 inclusions occur in the ALS-bearing Guam disease, but human autopsy data do not establish a direct aggregation-to-motor-neuron-loss sequence.

Show evidence (2 references)

PMID:18843496 SUPPORT Human Clinical

"Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions involving multiple nerve fiber tracts occurred in both the ALS and PDC types, reinforcing the concept that these forms are part of the same disorder."

Direct Guam autopsy evidence establishes TDP-43-positive inclusions in both forms.

PMID:17713769 SUPPORT Human Clinical

"Spinal cord pathology of G-PDC or G-ALS was characterized by tau positive tangles as well as TDP-43 positive inclusions in lower motor neurons and glial cells."

Directly localizes TDP-43-positive inclusions to lower motor neurons and glia in sampled Guam PDC and Guam ALS spinal cords.

Motor Neuron Degeneration

Degeneration affecting upper- and lower-motor-neuron systems produces the ALS component and associated pyramidal and denervation signs. This observed regional outcome is not assigned exclusively to tau, TDP-43, or BMAA.

Observed Guam Multiple-Proteinopathy and Regional Neurodegeneration

motor neuron CL:0000100

spinal cord UBERON:0002240

Downstream

Motor Neuron Disease (ALS) Motor-system degeneration produces the ALS-predominant component of the disease spectrum.

Hyperreflexia Upper-motor-neuron and pyramidal-system dysfunction produces hyperactive stretch reflexes.

Distal Amyotrophy Lower-motor-neuron denervation produces distal spinal muscular atrophy.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Hyperreflexia and spinal muscular atrophy, developing mainly in the distal extremities, are frequently observed."

The upper- and lower-motor-neuron signs support motor-system degeneration in Guam PDC.

Nigrostriatal Dopaminergic Dysfunction

PET demonstrates reduced presynaptic striatal fluorodopa uptake in Guam PDC, with intermediate reductions in Guam ALS and reductions in some clinically normal Guamanians. This is a living-subject readout of nigrostriatal injury, not a disease-specific diagnostic signature.

Observed Guam Multiple-Proteinopathy and Regional Neurodegeneration

striatum UBERON:0002435

Downstream

Atypical Parkinsonism Presynaptic nigrostriatal dopaminergic dysfunction produces the parkinsonian component.

Rigidity Dopaminergic and extrapyramidal dysfunction contributes to marked rigidity.

Gait Disturbance Bradykinesia, rigidity, and impaired postural reflexes disrupt gait.

Show evidence (1 reference)

PMID:2375693 SUPPORT Human Clinical

"The nigrostriatal lesions in the subjects with amyotrophic lateral sclerosis and the Guamanian normal subjects are examples of subclinical neuronal damage demonstrable in living subjects with positron emission tomography."

Directly establishes a living-subject nigrostriatal lesion extending beyond clinically manifest parkinsonism.

Dementia-Associated Neuronal Dysfunction

Progressive cognitive deterioration accompanies the Guam PDC form. The entry conservatively represents a neuronal-system outcome without assigning a specific cortical circuit or asserting that one protein lesion alone causes it.

Observed Guam Multiple-Proteinopathy and Regional Neurodegeneration

neuron CL:0000540

Downstream

Dementia Progressive neuronal dysfunction manifests clinically as dementia.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Dementia in PDC is characterized by a progressive dulling of all intellectual faculties, recent memory deﬁcits, disorien- tation in time, place and then person, as well as personality and behavioral changes."

Directly describes progressive cognitive-system dysfunction in Guam PDC.

L-BMAA Neurotoxic Exposure

Dietary L-BMAA is retained as the trigger of an alternative cycad-toxin hypothesis. Guam ecosystem measurements and experimental systems make the route biologically plausible, but neither those observations nor this node establish that human exposure caused Guam ALS-PDC.

Cycad-Derived L-BMAA Neurotoxicity Model

Downstream

AMPA/Kainate Receptor Overactivation and Calcium Overload In spinal-cord cultures, BMAA activates AMPA/kainate receptors and preferentially raises motor-neuron intracellular calcium.

Tau-Dominant Neurofibrillary Pathology Chronic dietary BMAA produced tau tangles in a vervet model; translation to human Guam disease remains unproven.

Show evidence (2 references)

PMID:14612559 SUPPORT Other

"The biomagnification of BMAA through the Guam ecosystem fits a classic triangle of increasing concentrations of toxic compounds up the food chain."

Supports environmental bioaccumulation but does not establish a causal human exposure dose.

PMID:28598725 REFUTE Other

"The relationship of BMAA and ALS/PDC has never been proven, and the neurotoxic effects of BMAA seen in animals have only been noted after large doses that would involve unrealistic human exposures."

The critical review directly limits causal extrapolation from experimental exposure to Guam disease.

AMPA/Kainate Receptor Overactivation and Calcium Overload

In dissociated spinal-cord cultures, L-BMAA-dependent AMPA/kainate receptor activation produces preferential intracellular calcium rises in motor neurons. This is an in-vitro mechanism within the alternative BMAA model.

Cycad-Derived L-BMAA Neurotoxicity Model

motor neuron CL:0000100

calcium ion transmembrane transport GO:0070588 ↑ INCREASED

Downstream

Oxidative Stress in Vulnerable Motor Neurons BMAA-induced calcium stress accompanies selective ROS generation in cultured motor neurons.

Excitotoxic Motor Neuron Death AMPA/kainate receptor activation is required for BMAA-induced death in cultured motor neurons.

Show evidence (1 reference)

PMID:16764863 SUPPORT In Vitro

"Ca(2+)](i) rises and selective reactive oxygen species (ROS) generation in MNs with minimal effect on other spinal neurons."

Directly supports preferential motor-neuron calcium and ROS responses in culture.

Oxidative Stress in Vulnerable Motor Neurons

Selective ROS generation occurs in cultured motor neurons exposed to BMAA. The evidence is experimental and does not demonstrate oxidative stress as a measured lesion in Guam patients.

Cycad-Derived L-BMAA Neurotoxicity Model

motor neuron CL:0000100

response to oxidative stress GO:0006979 ↑ INCREASED

Downstream

Excitotoxic Motor Neuron Death Selective ROS generation accompanies BMAA-induced motor-neuron loss, but the experiment does not fully isolate ROS as the sole mediator.

Show evidence (1 reference)

PMID:16764863 SUPPORT In Vitro

"Ca(2+)](i) rises and selective reactive oxygen species (ROS) generation in MNs with minimal effect on other spinal neurons."

Direct evidence of selective ROS generation in cultured motor neurons.

Excitotoxic Motor Neuron Death

BMAA produces selective motor-neuron loss in mixed spinal-cord cultures. This experimentally observed cell-death node belongs only to the alternative BMAA hypothesis and is not treated as proof of the lesion in human Guam tissue.

Cycad-Derived L-BMAA Neurotoxicity Model

motor neuron CL:0000100

Downstream

Motor Neuron Degeneration Experimental motor-neuron death is a possible route to the human motor-system lesion, but cross-system translation is unresolved.

Show evidence (1 reference)

PMID:16764863 SUPPORT In Vitro

"BMAA was found to induce selective motor neuron (MN) loss in dissociated mixed spinal cord cultures at concentrations ( approximately 30 muM) significantly lower than those previously found to induce widespread neuronal degeneration."

Directly demonstrates selective motor-neuron loss in an in-vitro spinal-cord system.

✶

Histopathology

4

Widespread Mixed 3R/4R Tau Neurofibrillary Tangles

Widespread neurofibrillary tangles expressing both 3R and 4R tau are the most prominent postmortem hallmark. The finding is characteristic but was not reported as pathognomonic relative to other degenerative disorders.

Show evidence (1 reference)

PMID:21527311 SUPPORT Other

"The most prominent pathological hallmark is the widespread occurrence of neurofibrillary tangles which express the same balance of 3R and 4R tau that is found in Alzheimer disease."

Directly establishes the principal mixed-isoform tau finding.

CTE-Fold Tau Filaments

Cryo-electron microscopy identified CTE-fold tau filaments in the sampled Guam cerebral cortex and spinal cord. Structural similarity does not make Guam ALS-PDC equivalent to chronic traumatic encephalopathy and does not by itself identify an exogenous cause.

Show evidence (1 reference)

PMID:38100415 SUPPORT In Vitro

"Tau filaments had the chronic traumatic encephalopathy (CTE) fold, with variable amounts of Type I and Type II filaments."

Supports the structural fold in the sampled postmortem material without adopting the authors' separate etiologic inference.

TDP-43-Positive Neuronal and Glial Inclusions

TDP-43-positive inclusions occur in neurons, oligodendroglia, and astrocytes across both ALS and PDC forms; the cited source does not specify cytoplasmic localization in its available text.

Show evidence (2 references)

PMID:18843496 SUPPORT Human Clinical

"Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions involving multiple nerve fiber tracts occurred in both the ALS and PDC types, reinforcing the concept that these forms are part of the same disorder."

Direct autopsy evidence for TDP-43-positive neuronal and glial inclusions.

PMID:17713769 SUPPORT Human Clinical

"G-PDC was associated with cortical TDP-43 positive dystrophic neurites and neuronal and glial inclusions in gray and/or white matter."

Directly supports cortical TDP-43 neurites and inclusions in Guam PDC.

Variable Amyloid-Beta Plaques and Alpha-Synuclein Lewy Bodies

Sparse Aβ plaques and occasional α-synuclein Lewy bodies are variable co-pathologies. Histologic α-synuclein deposits are distinct from α-synuclein prion activity, which was not detected in the sampled cohorts.

Show evidence (2 references)

PMID:36952379 SUPPORT Human Clinical

"The amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC) of Guam is an endemic neurodegenerative disease that features widespread tau tangles, occasional α-synuclein Lewy bodies, and sparse β-amyloid (Aβ) plaques distributed in the central nervous system."

Directly establishes occasional Lewy bodies and sparse amyloid plaques.

PMID:36952379 SUPPORT In Vitro

"In ALS-PDC brain samples, we detected high titers of tau and Aβ prions, but we did not detect α-synuclein prions in either cohort."

Prevents conflation of occasional Lewy bodies with detectable α-synuclein prion activity.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

13

Digestive 1

Dysphagia HP:0002015

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Dysarthria and dysphagia occur in all PDC patients, usually as a result of both extrapyramidal and cortico-bulbar dysfunc- tion, compounded by advancing dementia [2]."

Directly supports dysphagia in the reviewed PDC series without extending the claim to ALS-predominant disease.

Eye 1

Abnormal Eye Movement Abnormality of eye movement HP:0000496

Show evidence (2 references)

PMID:3194062 SUPPORT Human Clinical

"We found abnormal supranuclear ocular or lid motility in all of 37 patients with Lytico-Bodig (amyotrophic lateral sclerosis/parkinsonism-dementia complex)."

Supports the phenotype in the examined series while preserving the cohort denominator and avoiding a universal disease-level frequency claim.

PMID:10525998 SUPPORT Human Clinical

"Ocular motility usually remains intact, although in rare cases vertical gaze, especially upward, ultimately becomes impaired."

Supports rare vertical-gaze impairment while conflicting with the all-patient frequency reported in the separate 37-patient ocular-motor series.

Musculoskeletal 1

Rigidity HP:0002063

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"In PDC, rigidity is so marked that postural deformities such as a generally flexed posture become rather prominent."

Directly documents marked rigidity in Guam PDC.

Nervous System 6

Atypical Parkinsonism HP:0001300

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Important diagnostic indicators of the illness include rigido-akinetic type Parkinsonism and severe dementia."

Directly identifies the rigido-akinetic parkinsonian component of Guam PDC.

Dementia HP:0000726

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Dementia in PDC is characterized by a progressive dulling of all intellectual faculties, recent memory deﬁcits, disorien- tation in time, place and then person, as well as personality and behavioral changes."

Directly describes progressive dementia in Guam PDC.

Bradykinesia HP:0002067

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Most PDC patients show bradykinesia and rigidity similar to what is seen with Parkinson’s disease, but more marked."

Directly supports bradykinesia in most PDC patients without extending the frequency to other forms.

Dysarthria HP:0001260

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Dysarthria and dysphagia occur in all PDC patients, usually as a result of both extrapyramidal and cortico-bulbar dysfunc- tion, compounded by advancing dementia [2]."

Directly supports dysarthria in the reviewed PDC series without extending the claim to ALS-predominant disease.

Gait Disturbance HP:0001288

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"This gait disturbance is due to bradykinesia, rigidity and impaired postural reﬂexes."

Directly describes the clinical intermediates underlying gait disturbance.

Hyperreflexia HP:0001347

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Hyperreflexia and spinal muscular atrophy, developing mainly in the distal extremities, are frequently observed."

Directly documents hyperreflexia in Guam PDC.

Other 4

Motor Neuron Disease (ALS) Amyotrophic lateral sclerosis HP:0007354

Show evidence (1 reference)

PMID:18843496 SUPPORT Human Clinical

"Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions involving multiple nerve fiber tracts occurred in both the ALS and PDC types, reinforcing the concept that these forms are part of the same disorder."

Supports ALS and PDC as clinical-pathologic forms of the same Guam disorder.

Mask-like Facies HP:0000298

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Masked, oily faces and reduced blinking develop in all PDC patients."

Directly supports mask-like facies in PDC without extending the frequency to other forms.

Distal Amyotrophy HP:0003693

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Hyperreflexia and spinal muscular atrophy, developing mainly in the distal extremities, are frequently observed."

Directly documents distal muscular atrophy in Guam PDC.

Linear Retinal Pigment Epitheliopathy

Show evidence (1 reference)

PMID:26153661 SUPPORT Human Clinical

"Prospectively, 15 of 50 cases with epitheliopathy developed amyotrophic lateral sclerosis/parkinsonism-dementia complex, compared to 4 of 189 cases without epitheliopathy (age- and sex-adjusted hazard ratio: 13.1; 95% CI: 4.0-43.1; P < 0.0001)."

Directly supports prospective association in the reported cohort without asserting etiologic causation or diagnostic specificity.

🧬

Genetic Associations

5

TRPM7 (Candidate T1482I gene-environment susceptibility allele in a proposed low-calcium, low-magnesium context.)

Gene: TRPM7 hgnc:17994 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (2 references)

PMID:16051700 SUPPORT Human Clinical

"We found a TRPM7 variant in a subset of ALS-G and PD-G patients that produces a protein with a missense mutation, T1482I."

Supports a variant in a subset rather than a disease-defining causal gene.

PMID:16051700 SUPPORT In Vitro

"However, heterologously expressed T1482I TRPM7 produces functional channels that show an increased sensitivity to inhibition by intracellular Mg2+."

Directly supports the altered channel property in a heterologous system.

Chromosome 12p D12S1617 susceptibility locus (Candidate linkage and allelic-association signal from a large, genetically isolated Guam sample; not a resolved causal gene or independently replicated disease mechanism.)

relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:19567404 SUPPORT Human Clinical

"D12S1617 on 12p gave the strongest evidence of linkage (maximum LOD score, Z(max) = 4.03) in our initial scan, with additional support in the complete case-control sample in the form of evidence of allelic association at this marker and another nearby marker."

Supports a candidate linkage/association locus in the sampled isolate, not a causal variant or gene.

MAPT-region susceptibility signal (Supportive, non-causal linkage evidence at the chromosome 17 MAPT region.)

Gene: MAPT hgnc:6893 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (1 reference)

PMID:19567404 SUPPORT Human Clinical

"We found significant evidence for two regions with novel ALS/PDC loci on chromosome 12 and supportive evidence for the involvement of the MAPT region on chromosome 17."

Directly supports only a regional susceptibility signal, with no causal MAPT variant established.

C9orf72 repeat-expansion hypothesis (Pathogenic repeat expansion tested and refuted as a cause of Chamorro Guam ALS-PDC.)

Gene: C9orf72 hgnc:28337 relationship_type: DISPUTED variant_origin: GERMLINE

Show evidence (1 reference)

PMID:23588498 REFUTE Human Clinical

"All Chamorro participants with ALS and PDC and control subjects had normal repeats, ranging from 2 to 17 copies."

Refutes pathogenic C9orf72 repeat expansion in the 24 ALS cases, 22 PDC cases, and 43 controls studied; it is not a claim about every possible case.

LRRK2 mutation hypothesis (Pathogenic point mutations tested and refuted as a cause in the sampled population.)

Gene: LRRK2 hgnc:18618 relationship_type: DISPUTED variant_origin: GERMLINE

Show evidence (1 reference)

PMID:23588498 REFUTE Human Clinical

"No pathogenic LRRK2 mutations were found."

Refutes pathogenic LRRK2 point mutations in the study series without asserting exhaustive exclusion of every possible LRRK2 variant.

💊

Medical Actions

1

Levodopa for Early Parkinsonian Symptoms

Action: Pharmacotherapy NCIT:C15986

Agent: L-dopa CHEBI:15765

Some early-stage cases were reported to respond to levodopa. This is limited symptomatic evidence from a clinical overview, not evidence of durable benefit, disease modification, or efficacy across the ALS-PDC spectrum.

Target Phenotypes: Parkinsonism HP:0001300

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"These cases occasionally present with the same clinical picture and response to levodopa in the early stage."

Supports only occasional early symptomatic response; no controlled or disease-modifying treatment inference is made.

🌍

Environmental Factors

1

Cycad-Ecosystem L-BMAA Ingestion (Candidate)

Ingestion of L-BMAA through cycad-associated foods, including proposed trophic transfer through flying foxes, is a historically important exposure hypothesis. Ecosystem biomagnification was reported, but a causal human dose and a causal relationship to Guam ALS-PDC have not been established.

Show evidence (3 references)

PMID:14612559 SUPPORT Other

"Flying foxes are a prized food item of the indigenous Chamorro people who boil them in coconut cream and eat them whole."

Supports a proposed ingestion route but not a causal or sufficient human exposure dose.

PMID:28598725 REFUTE Other

"The review concludes that the hypothesis of a causal BMAA neurodegenerative disease relationship is not supported by existing data."

Directly records the critical review's conclusion against a demonstrated causal relationship.

PMID:36952379 SUPPORT Other

"Extensive studies of genetic or environmental factors have failed to identify a cause of ALS-PDC."

Confirms that environmental causation remains unresolved.

🔬

Diagnosis

6

Neurological Physical Examination

Examination identifies the combined rigido-akinetic, pyramidal, lower-motor-neuron, gait, and cognitive syndrome and helps assign a clinical form. The findings are syndromic rather than etiologically confirmatory.

physical examination NCIT:C20989

Results: Rigido-akinetic parkinsonism, rigidity, gait disturbance, hyperreflexia, distal amyotrophy, or an ALS syndrome in the appropriate Guam context.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Important diagnostic indicators of the illness include rigido-akinetic type Parkinsonism and severe dementia."

Establishes key examination indicators of the PDC-predominant form.

Cognitive Assessment

Cognitive assessment characterizes the progressive global dementia component but does not distinguish Guam ALS-PDC from other neurodegenerative diseases.

cognitive assessment NCIT:C165543

Results: Progressive global intellectual decline with memory, orientation, personality, and behavioral change.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Dementia in PDC is characterized by a progressive dulling of all intellectual faculties, recent memory deﬁcits, disorien- tation in time, place and then person, as well as personality and behavioral changes."

Supports the cognitive domains requiring assessment without validating a specific test instrument.

Striatal Fluorodopa PET

18F-6-fluorodopa PET can demonstrate presynaptic nigrostriatal dysfunction, but reduced uptake also occurred in Guam ALS and clinically normal Guam subjects and therefore is not confirmatory.

positron emission tomography procedure NCIT:C17007

Results: Reduced striatal 18F-6-fluorodopa uptake, with the strongest reduction in clinically parkinsonian subjects.

Show evidence (1 reference)

PMID:2375693 SUPPORT Human Clinical

"The nigrostriatal lesions in the subjects with amyotrophic lateral sclerosis and the Guamanian normal subjects are examples of subclinical neuronal damage demonstrable in living subjects with positron emission tomography."

Supports PET detection of living-subject neuronal damage while demonstrating limited diagnostic specificity.

Postmortem Neuropathologic Examination

A 2011 review reported that Guam and Kii ALS/PDC could then be confirmed only by postmortem examination. This is retained as historical diagnostic context, not a timeless claim that no premortem biomarker can ever be available.

autopsy procedure NCIT:C25153

Results: Widespread mixed 3R/4R tau neurofibrillary pathology with associated protein lesions in a compatible clinicogeographic syndrome.

Show evidence (1 reference)

PMID:21527311 SUPPORT Other

"At present, ALS/PDC of Guam and the Kii Peninsula can be confirmed only by postmortem examination."

Records the review's 2011 confirmation standard with explicit temporal scope.

Ocular Motor Examination

Examination can identify supranuclear ocular and eyelid motor abnormalities, but the evidence is a single 37-patient series and does not validate a stand-alone diagnostic test.

eye examination NCIT:C38060

Results: Heterogeneous supranuclear ocular or lid motor abnormalities.

Show evidence (1 reference)

PMID:3194062 SUPPORT Human Clinical

"We found abnormal supranuclear ocular or lid motility in all of 37 patients with Lytico-Bodig (amyotrophic lateral sclerosis/parkinsonism-dementia complex)."

Supports examination yield in the reported series, not specificity or a validated diagnostic threshold.

Retinal Examination for Linear Pigment Epitheliopathy

Retinal examination may identify the associated linear pigment epitheliopathy. Its prospective association makes it a candidate risk marker, not a confirmatory test for ALS-PDC.

eye examination NCIT:C38060

Results: Presence or absence of linear retinal pigment epitheliopathy.

Show evidence (1 reference)

PMID:26153661 SUPPORT Human Clinical

"The epitheliopathy was present in 59.7% (117 of 196) patients with amyotrophic lateral sclerosis/parkinsonism-dementia complex, but in only 24.7% (178 of 722) of subjects who were neurologically asymptomatic"

Supports association and incomplete sensitivity/specificity, which is why the examination is not represented as confirmatory.

🩻

Imaging Findings

1

Reduced Striatal 18F-6-Fluorodopa Uptake on PET

PET demonstrates reduced striatal presynaptic fluorodopa uptake in Guam parkinsonism. Intermediate or reduced uptake also occurred in ALS and some clinically normal Guamanians, so the finding is not disease-specific.

Pet

reduced striatal 18F-6-fluorodopa uptake striatum UBERON:0002435

A functional correlate of nigrostriatal damage, not a confirmatory biomarker; subclinical abnormalities occurred outside clinically parkinsonian subjects.

Show evidence (1 reference)

PMID:2375693 SUPPORT Human Clinical

"The parkinsonian subjects all had significantly reduced striatal 18F-6-fluorodopa uptake. The group with amyotrophic lateral sclerosis had significantly reduced uptake that was intermediate between that of the control group and the parkinsonian group. Two Guamanian normal subjects had reduced..."

Directly documents the finding and its limited specificity.

📈

Progression

3

Reported age at onset of Guam ALS

ALS-predominant Age: Mean 49.9 ± 9.6 years in the reported 70-case Guam ALS series

This historical cohort estimate is specific to the ALS-predominant form and is not generalized to PDC-predominant or mixed presentations.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Table 1 Age of onset Guam ALS Guam PD Male Female Total Male Female Total No. 43 27 70 45 25 70 Mean (yr.) 51.2 47.8 49.9 56.9 62.4 58.9 S.D. (yr.) 8.6 10.7 9.6 7.4 8.9 8.3"

The table reports a total-cohort mean of 49.9 years and standard deviation of 9.6 years for 70 Guam ALS cases.

Reported age at onset of Guam PDC

PDC-predominant Age: Mean 58.9 ± 8.3 years in the reported 70-case PDC series

This historical cohort estimate is specific to PDC-predominant disease and is not generalized to ALS-predominant or mixed presentations.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"In 1980, Murakami reported the average age at onset of PDC among 70 cases to be 58.9 ± 8.3 years"

Directly reports the mean and standard deviation in the 70-case PDC series.

Progressive PDC course

PDC-predominant Duration: 1 to 15 years; mean 5.0 ± 2.6 years in the reported 70-case series

The estimate applies to the PDC cohort and is not generalized to every ALS-predominant presentation.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"The durations of the disease among 70 cases ranged from 1 to 15 years, with an average duration of 5.0 ± 2.6 years"

The Guam PDC series provides a subtype-scoped duration estimate.

🌍

Epidemiology

4

Historical Guam hyperendemicity

Mid-twentieth-century Guam surveys reported ALS incidence, prevalence, and mortality roughly 50-100 times rates reported elsewhere.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"Clinical and epidemiologic studies from 1949 to 1954 demonstrated a phenomenal frequency of ALS (Lytico) on Guam; its incidence, prevalence, and mortality rates were estimated to be about 50-100 times as high as those reported elsewhere."

Documents the historical relative excess without inventing an absolute rate.

Declining Guam prevalence

Later Guam autopsy series were assembled against a background of declining disease prevalence; the decline motivates environmental hypotheses but does not establish a specific exposure as causal.

Show evidence (1 reference)

PMID:18843496 SUPPORT Human Clinical

"Since the prevalence is declining, we examined brain tissue from 35 clinically diagnosed Chamorro patients with ALS/PDC and two Chamorro controls autopsied between 1946 and 2006, to determine if distinct variations in the pathology could be identified up to this time."

Directly documents declining prevalence in the Guam cohort context.

Divergent late-century incidence trajectories

Case-registration data from 1940-1999 showed a sustained decline in Guam ALS incidence, whereas PDC incidence declined until the late 1980s and then rose slightly over 1980-1999. The authors considered the rapid change inconsistent with a purely genetic explanation, but the study did not identify a specific causal exposure.

Show evidence (1 reference)

PMID:12522022 SUPPORT Human Clinical

"The results of this study confirmed that the incidence of ALS declined steadily during the past 40 years. The incidence of PDC also declined until the late 1980s but, unlike ALS, showed a slight increase from 1980 to 1999."

Directly supports the distinct ALS and PDC incidence trajectories without treating incidence as prevalence or inferring a particular exposure.

Guam and Rota geographic focus

The historical Mariana syndrome affected Chamorros on Guam and Rota; this record does not merge the distinct Kii and West Papua foci into the MONDO Guam disease identity.

Show evidence (1 reference)

PMID:28598725 SUPPORT Other

"A neurodegenerative disease with a spectrum of symptoms that affected Chamorros in Guam, Rota, and other Mariana Islands was initially described in a 1936 case history of a patient exhibiting symptoms of both Parkinsonism and dementia."

Supports the bounded Guam/Rota Mariana scope used for this entry.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex:

Parkinson disease MONDO:0005180

Overlapping Features Parkinson disease overlaps with the bradykinetic-rigid presentation of Guam PDC. Dementia, motor-neuron signs, rapid progression, and the Mariana clinicogeographic context favor ALS-PDC, but no single premortem discriminator has been validated.

Distinguishing Features

Guam PDC progresses relatively rapidly compared with Parkinson disease.
Coexisting dementia and upper- or lower-motor-neuron signs favor the Guam spectrum.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"PDC must be diagnosed so as to differentiate it from other disorders such as Parkinson’s disease, Alzheimer’s disease, progressive supranuclear palsy (PSP),"

Directly identifies Parkinson disease as a clinical differential.

Alzheimer disease MONDO:0004975

Overlapping Features Alzheimer disease overlaps through dementia, tau tangles, and variable Aβ pathology. Guam ALS-PDC adds a characteristic motor spectrum and a molecular tau/Aβ-prion signature that differed from sporadic Alzheimer disease in one postmortem bioassay cohort.

Distinguishing Features

Guam ALS-PDC may include atypical parkinsonism and upper- or lower-motor-neuron disease.
Postmortem molecular signature differed from sporadic Alzheimer disease in the cited study.

Show evidence (1 reference)

PMID:36952379 SUPPORT In Vitro

"Applying partial least squares regression to all biochemical and prion infectivity measurements, we demonstrated that the ALS-PDC cohort has a unique molecular signature distinguishable from AD."

Supports a postmortem biochemical distinction in the sampled cohorts, not a validated premortem differential test.

Progressive supranuclear palsy MONDO:0019037

Overlapping Features Progressive supranuclear palsy overlaps through atypical parkinsonism, rigidity, gait impairment, supranuclear ocular motor dysfunction, and tauopathy. Guam ALS-PDC may additionally show dementia and motor-neuron involvement in its characteristic geographic and familial setting.

Distinguishing Features

Motor-neuron disease within the ALS-PDC spectrum is not a defining PSP feature.
Historical Guam or Rota ancestry and epidemiologic context support ALS-PDC but are not independently diagnostic.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"PDC must be diagnosed so as to differentiate it from other disorders such as Parkinson’s disease, Alzheimer’s disease, progressive supranuclear palsy (PSP),"

Directly identifies progressive supranuclear palsy as a clinical differential.

Corticobasal degeneration Not Yet Curated MONDO:0022308

Overlapping Features Corticobasal degeneration overlaps through atypical parkinsonism, cortical dysfunction, and tauopathy. Motor-neuron involvement and the Mariana clinicogeographic context may support Guam ALS-PDC but are not independently diagnostic.

Distinguishing Features

Motor-neuron disease within the ALS-PDC spectrum is not a defining feature of corticobasal degeneration.
Historical Guam or Rota ancestry and epidemiologic context support ALS-PDC but are not independently diagnostic.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"progressive supranuclear palsy (PSP), corticobasal degenera- tion (CBD),"

Directly identifies corticobasal degeneration as a clinical differential.

Dementia with Lewy bodies MONDO:0007488

Overlapping Features Dementia with Lewy bodies overlaps through dementia and parkinsonism. The Guam spectrum may additionally include motor-neuron disease and a distinct historical Mariana epidemiologic context, but no single premortem discriminator has been validated.

Distinguishing Features

Motor-neuron disease within the ALS-PDC spectrum is not a defining feature of Lewy body dementia.
Historical Guam or Rota ancestry and epidemiologic context support ALS-PDC but are not independently diagnostic.

Show evidence (1 reference)

PMID:10525998 SUPPORT Human Clinical

"dementia with Lewy bodies (DLB)."

Directly identifies dementia with Lewy bodies as a clinical differential.

🧫

Experimental Models

1

Guam PDC patient-derived iPSC neural-cell resource IPSC_DERIVED_MODEL

The resource provides patient-derived neural lineages for testing genetic and environmental hypotheses. The report establishes lineage generation and marker expression, not a disease-specific cellular phenotype, and the one-case, one-control design cannot separate disease effects from individual background.

Organism

human NCBITaxon:9606

Cell source

iPSCs from one PDC-affected Guamanian Chamorro woman and one age- and sex-matched healthy Chamorro resident of Saipan

Culture

iPSC-derived human neural progenitor cells, neurons, astrocyte progenitors, and mature astrocytes

Publication

PMID:41332773

Preprint indexed in PubMed; no disease-specific cellular abnormality was claimed in the available abstract.

Show evidence (1 reference)

PMID:41332773 SUPPORT In Vitro

"Development of these patient-derived iPSCs provides a human model for evaluating the role of environmental (e.g., cycad toxins) and genetic factors in ALS-PDC and possibly other related neurodegenerative diseases."

Supports the system as a hypothesis-testing resource, not as a validated phenocopy of ALS-PDC.

🐁

Animal Models

3

Mouse (Mus musculus) Exposure model

Washed cycad flour produced progressive motor and cognitive dysfunction and neurodegeneration in cortex, hippocampus, substantia nigra, olfactory bulb, and spinal cord. The study detected little of several previously proposed toxins and identified BSSG as the most toxic isolated component; this is a partial phenocopy, not proof of human causation.

Species

Mouse (Mus musculus)

Background

Adult male CD-1 mice fed washed cycad-flour pellets

Show evidence (1 reference)

PMID:12095162 SUPPORT Model Organism

"Cycad-fed animals showed early evidence of progressive motor and cognitive dysfunctions. Neurodegeneration measured using TUNEL and caspase-3 labeling was found in neocortex, various hippocampal fields, substantia nigra, olfactory bulb, and spinal cord."

Directly supports the model's behavioral and anatomic findings.

Mouse (Mus musculus) Exposure model

Dietary BSSG produced motor deficits, spinal motor-neuron loss, altered glutamate-transporter labeling, gliosis, and nigrostriatal changes. Different exposure schedules and backgrounds were used, and the model does not establish BSSG exposure or dose in human Guam ALS-PDC.

Species

Mouse (Mus musculus)

Background

Adult CD-1 and C57BL/6 mice chronically fed beta-sitosterol beta-D-glucoside (BSSG)

Show evidence (1 reference)

PMID:18196479 SUPPORT Model Organism

"C57BL/6 mice fed BSSG-treated pellets for 10 weeks exhibited progressive loss of motor neurons in the lumbar spinal cord that continued to worsen even after the BSSG exposure ended."

Directly supports progressive post-exposure motor-neuron loss in one of the two reported mouse backgrounds.

Vervet monkey (Chlorocebus sabaeus) Exposure model

Chronic BMAA exposure induced neurofibrillary tangles and amyloid deposits in vervets; L-serine reduced tangle density in the model. The experiment supports a preclinical hypothesis but does not establish comparable human exposure, therapeutic efficacy, or BMAA causation in Guam ALS-PDC.

Species

Vervet monkey (Chlorocebus sabaeus)

Background

Chronic dietary BMAA exposure, with an L-serine co-treatment arm

Show evidence (1 reference)

PMID:26791617 SUPPORT Model Organism

"In replicated experiments, we found that chronic dietary exposure to a cyanobacterial toxin present in the traditional Chamorro diet, β-N-methylamino-l-alanine (BMAA), triggers the formation of both NFT and β-amyloid deposits similar in structure and density to those found in brain tissues of..."

Supports neuropathologic similarity in a primate exposure model, not human disease causation.

{ }

Source YAML

click to show

name: Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex
creation_date: "2026-06-11T00:00:00Z"
category: Complex
parents:
- Motor Neuron Disease
- Neurodegenerative Disease
disease_term:
  preferred_term: Guam amyotrophic lateral sclerosis-parkinsonism-dementia complex
  term:
    id: MONDO:0007104
    label: amyotrophic lateral sclerosis-parkinsonism-dementia complex
synonyms:
- Guam disease
- Lytico-Bodig disease
description: >-
  Amyotrophic lateral sclerosis-parkinsonism-dementia complex (ALS-PDC), locally
  called lytico-bodig, is a progressive neurodegenerative disease historically
  concentrated among Chamorro people on Guam and Rota. This MONDO-scoped entry
  covers that Mariana focus and its overlapping ALS-predominant,
  parkinsonism-dementia-predominant, and mixed presentations. Similar syndromes
  reported from the Kii Peninsula and West Papua are retained only as comparison
  entities because their epidemiology and genetic findings are not interchangeable
  with the Guam/Rota disease. Guam ALS-PDC has widespread tau pathology, TDP-43
  inclusions, and variable amyloid-beta and alpha-synuclein co-pathology, but its
  cause remains unresolved. Historical cycad-derived L-BMAA exposure and mineral
  gene-environment interactions are hypotheses rather than established etiologies;
  no causative gene has been established. A 2011 review reported that confirmation
  remained postmortem-only and called for premortem biomarkers; no treatment claim
  is inferred in this entry.
has_subtypes:
- name: ALS-predominant
  description: >-
    Presentation dominated by upper- and lower-motor-neuron disease within the
    Guam ALS-PDC spectrum.
  evidence:
  - reference: PMID:18843496
    reference_title: "Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions
      involving multiple nerve fiber tracts occurred in both the ALS and PDC types,
      reinforcing the concept that these forms are part of the same disorder.
    explanation: Human Guam autopsies identify ALS and PDC clinical-pathologic forms within one disorder.
- name: PDC-predominant
  display_name: Parkinsonism-dementia-predominant
  description: >-
    Presentation dominated by rigido-akinetic parkinsonism and progressive
    dementia, with variable motor-neuron signs.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Important diagnostic indicators of the illness include rigido-akinetic type
      Parkinsonism and severe dementia.
    explanation: The Guam clinical overview defines the core PDC presentation.
- name: Mixed ALS-PDC
  description: >-
    Presentation in which motor-neuron disease, parkinsonism, and dementia overlap
    clinically rather than segregating into a single predominant form.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These mixed-syndrome patients can be seen as clear support for the view that
      Guam ALS and PDC constitute a single mixed disease entity with a spectrum of
      clinical expression.
    explanation: The clinical review explicitly supports a mixed ALS-PDC spectrum.
progression:
- phase: Reported age at onset of Guam ALS
  subtype: ALS-predominant
  age_range: Mean 49.9 ± 9.6 years in the reported 70-case Guam ALS series
  notes: >-
    This historical cohort estimate is specific to the ALS-predominant form and
    is not generalized to PDC-predominant or mixed presentations.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Table 1 Age of onset Guam ALS Guam PD Male Female Total Male Female Total
      No. 43 27 70 45 25 70 Mean (yr.) 51.2 47.8 49.9 56.9 62.4 58.9 S.D.
      (yr.) 8.6 10.7 9.6 7.4 8.9 8.3
    explanation: >-
      The table reports a total-cohort mean of 49.9 years and standard deviation
      of 9.6 years for 70 Guam ALS cases.
- phase: Reported age at onset of Guam PDC
  subtype: PDC-predominant
  age_range: Mean 58.9 ± 8.3 years in the reported 70-case PDC series
  notes: >-
    This historical cohort estimate is specific to PDC-predominant disease and
    is not generalized to ALS-predominant or mixed presentations.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 1980, Murakami reported the average age at onset of PDC among 70 cases
      to be 58.9 ± 8.3 years
    explanation: Directly reports the mean and standard deviation in the 70-case PDC series.
- phase: Progressive PDC course
  subtype: PDC-predominant
  duration: 1 to 15 years; mean 5.0 ± 2.6 years in the reported 70-case series
  notes: >-
    The estimate applies to the PDC cohort and is not generalized to every
    ALS-predominant presentation.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The durations of the disease among 70 cases ranged from 1 to 15 years, with
      an average duration of 5.0 ± 2.6 years
    explanation: The Guam PDC series provides a subtype-scoped duration estimate.
epidemiology:
- name: Historical Guam hyperendemicity
  description: >-
    Mid-twentieth-century Guam surveys reported ALS incidence, prevalence, and
    mortality roughly 50-100 times rates reported elsewhere.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical and epidemiologic studies from 1949 to 1954 demonstrated a
      phenomenal frequency of ALS (Lytico) on Guam; its incidence, prevalence,
      and mortality rates were estimated to be about 50-100 times as high as
      those reported elsewhere.
    explanation: Documents the historical relative excess without inventing an absolute rate.
- name: Declining Guam prevalence
  description: >-
    Later Guam autopsy series were assembled against a background of declining
    disease prevalence; the decline motivates environmental hypotheses but does
    not establish a specific exposure as causal.
  evidence:
  - reference: PMID:18843496
    reference_title: "Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since the prevalence is declining, we examined brain tissue from 35
      clinically diagnosed Chamorro patients with ALS/PDC and two Chamorro
      controls autopsied between 1946 and 2006, to determine if distinct
      variations in the pathology could be identified up to this time.
    explanation: Directly documents declining prevalence in the Guam cohort context.
- name: Divergent late-century incidence trajectories
  description: >-
    Case-registration data from 1940-1999 showed a sustained decline in Guam ALS
    incidence, whereas PDC incidence declined until the late 1980s and then rose
    slightly over 1980-1999. The authors considered the rapid change inconsistent
    with a purely genetic explanation, but the study did not identify a specific
    causal exposure.
  evidence:
  - reference: PMID:12522022
    reference_title: "Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results of this study confirmed that the incidence of ALS declined
      steadily during the past 40 years. The incidence of PDC also declined until
      the late 1980s but, unlike ALS, showed a slight increase from 1980 to 1999.
    explanation: >-
      Directly supports the distinct ALS and PDC incidence trajectories without
      treating incidence as prevalence or inferring a particular exposure.
- name: Guam and Rota geographic focus
  description: >-
    The historical Mariana syndrome affected Chamorros on Guam and Rota; this
    record does not merge the distinct Kii and West Papua foci into the MONDO
    Guam disease identity.
  evidence:
  - reference: PMID:28598725
    reference_title: "A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A neurodegenerative disease with a spectrum of symptoms that affected
      Chamorros in Guam, Rota, and other Mariana Islands was initially described
      in a 1936 case history of a patient exhibiting symptoms of both Parkinsonism
      and dementia.
    explanation: Supports the bounded Guam/Rota Mariana scope used for this entry.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_guam_multiple_proteinopathy
  hypothesis_label: Observed Guam Multiple-Proteinopathy and Regional Neurodegeneration
  status: CANONICAL
  description: >-
    The default disease model is etiology-agnostic: observed tau-dominant
    neurofibrillary pathology and TDP-43 inclusions accompany degeneration of
    motor and nigrostriatal systems and neuronal pathology accompanying cognitive
    manifestations. Human studies establish the
    lesions and clinical spectrum but do not establish which protein lesion is
    primary or the direction of causation between them.
  applies_to_subtypes:
  - ALS-predominant
  - PDC-predominant
  - Mixed ALS-PDC
  evidence:
  - reference: PMID:18843496
    reference_title: "Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions
      involving multiple nerve fiber tracts occurred in both the ALS and PDC types,
      reinforcing the concept that these forms are part of the same disorder.
    explanation: Guam autopsy evidence supports the shared mixed-proteinopathy spectrum.
  - reference: PMID:36952379
    reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In ALS-PDC brain samples, we detected high titers of tau and Aβ prions,
      but we did not detect α-synuclein prions in either cohort.
    explanation: Cellular bioassays of human brain extracts establish tau and amyloid-beta prion activity while distinguishing it from alpha-synuclein prion activity.
- hypothesis_group_id: cycad_bmaa_neurotoxicity_model
  hypothesis_label: Cycad-Derived L-BMAA Neurotoxicity Model
  status: ALTERNATIVE
  description: >-
    Chronic dietary L-BMAA exposure through traditional cycad-associated foods is
    proposed to cause glutamate-receptor-mediated motor-neuron injury and, based
    on a primate model, tau and amyloid-beta pathology. The mechanistic steps are
    experimentally supported in cells and vervets, but human Guam causation is
    not established and a critical review found the causal hypothesis unsupported.
  evidence:
  - reference: PMID:26791617
    reference_title: Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In replicated experiments, we found that chronic dietary exposure to a
      cyanobacterial toxin present in the traditional Chamorro diet,
      β-N-methylamino-l-alanine (BMAA), triggers the formation of both NFT and
      β-amyloid deposits similar in structure and density to those found in
      brain tissues of Chamorros who died with ALS/PDC.
    explanation: Vervet experiments support the model but cannot establish human Guam causation.
  - reference: PMID:28598725
    reference_title: "A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans."
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      The review concludes that the hypothesis of a causal BMAA neurodegenerative
      disease relationship is not supported by existing data.
    explanation: A critical review directly challenges the human causal interpretation.
pathophysiology:
- name: Tau-Dominant Neurofibrillary Pathology
  description: >-
    Widespread neuronal tau tangles are the dominant, consistently observed
    postmortem lesion in Guam ALS-PDC. Human bioassays also detect abundant tau
    prion activity. These observations establish the pathology but not its
    initiating cause or whether tau is the sole driver of regional neuronal loss.
  role: central_effector
  mechanism_confidence: ESTABLISHED
  biological_scale: TISSUE
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
    modifier: INCREASED
  evidence:
  - reference: PMID:36952379
    reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC)
      of Guam is an endemic neurodegenerative disease that features widespread
      tau tangles, occasional α-synuclein Lewy bodies, and sparse β-amyloid (Aβ)
      plaques distributed in the central nervous system.
    explanation: Directly establishes widespread tau tangles in Guam ALS-PDC.
  - reference: PMID:21527311
    reference_title: "The ALS/PDC syndrome of Guam: potential biomarkers for an enigmatic disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The most prominent pathological hallmark is the widespread occurrence of
      neurofibrillary tangles which express the same balance of 3R and 4R tau
      that is found in Alzheimer disease.
    explanation: The Guam review identifies widespread mixed 3R/4R tangles as the principal pathologic hallmark.
  - reference: PMID:38100415
    reference_title: Tau filaments from amyotrophic lateral sclerosis/parkinsonism-dementia complex adopt the CTE fold.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here, we used electron cryo-microscopy to determine the structures of tau
      filaments from the cerebral cortex of three cases of ALS/PDC from Guam and
      eight cases from Kii, as well as from the spinal cord of two of the Guam cases.
      Tau filaments had the chronic traumatic encephalopathy (CTE) fold, with
      variable amounts of Type I and Type II filaments.
    explanation: >-
      Establishes the filament fold in the three sampled Guam cortices and two
      sampled Guam spinal cords; it does not establish why that fold formed.
  - reference: PMID:41509476
    reference_title: Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC) features CTE-like tau seeds in brain and spinal cord.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      First, we confirmed the detection of tau seeding activity in ALS/PDC brain
      samples in tau biosensor cells. Notably, we could also detect potent tau
      seeding activity in spinal cord.
    explanation: >-
      This PubMed-indexed bioRxiv preprint supports tau-seeding activity in sampled
      Guam brain and spinal-cord extracts; it remains pending peer review and does
      not establish the initiating cause.
  downstream:
  - target: Dementia-Associated Neuronal Dysfunction
    description: >-
      Neocortical tau pathology accompanies the dementia-bearing disease, but
      the human evidence does not resolve the causal intermediates or establish
      tau as the sole cause of cognitive decline.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:36952379
      reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We found that all of the neocortical brain samples from 20 donors with
        ALS-PDC contained tau prions, but none of the samples had detectable
        α-synuclein prions.
      explanation: >-
        Human neocortical tissue supports regional tau involvement, while the
        direction from tau pathology to cognitive dysfunction remains inferential.
  - target: Nigrostriatal Dopaminergic Dysfunction
    description: >-
      Tau pathology and presynaptic dopaminergic dysfunction coexist in the PDC
      form; a direct tau-to-nigrostriatal causal route has not been demonstrated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:18843496
      reference_title: "Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Guam ALS/PDC is a severe tangle forming disorder endemic to Guam with
        features overlapping such neurodegenerative disorders as Alzheimer
        disease (AD), Parkinson disease (PD), progressive supranuclear palsy
        (PSP), ALS, corticobasal degeneration (CBD) and pallido-ponto-nigral
        degeneration (PPND).
      explanation: Connects the Guam tangle disorder to its parkinsonian clinical-pathologic context without proving causality.
    - reference: PMID:2375693
      reference_title: Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The parkinsonian subjects all had significantly reduced striatal 18F-6-fluorodopa uptake.
      explanation: Independently establishes the nigrostriatal dopaminergic lesion in living Guam PDC subjects.
- name: TDP-43-Positive Cellular Inclusions
  conforms_to: "tdp43_proteinopathy#Cytoplasmic TDP-43 Aggregation"
  description: >-
    TDP-43-positive neuronal and glial inclusions occur in Guam ALS-PDC across
    both ALS and PDC forms. The available Guam evidence establishes
    inclusion-positive cells but does not specify cytoplasmic localization.
  role: central_effector
  mechanism_confidence: ESTABLISHED
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:18843496
    reference_title: "Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions
      involving multiple nerve fiber tracts occurred in both the ALS and PDC types,
      reinforcing the concept that these forms are part of the same disorder.
    explanation: Direct Guam autopsy evidence establishes TDP-43-positive inclusions in both forms.
  - reference: PMID:17713769
    reference_title: Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Spinal cord pathology of G-PDC or G-ALS was characterized by tau positive
      tangles as well as TDP-43 positive inclusions in lower motor neurons and
      glial cells.
    explanation: >-
      Directly localizes TDP-43-positive inclusions to lower motor neurons and
      glia in sampled Guam PDC and Guam ALS spinal cords.
  downstream:
  - target: Motor Neuron Degeneration
    description: >-
      TDP-43 inclusions occur in the ALS-bearing Guam disease, but human autopsy
      data do not establish a direct aggregation-to-motor-neuron-loss sequence.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:18843496
      reference_title: "Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions
        involving multiple nerve fiber tracts occurred in both the ALS and PDC types,
        reinforcing the concept that these forms are part of the same disorder.
      explanation: Supports coexistence in the ALS form while leaving causal direction unresolved.
- name: Motor Neuron Degeneration
  description: >-
    Degeneration affecting upper- and lower-motor-neuron systems produces the
    ALS component and associated pyramidal and denervation signs. This observed
    regional outcome is not assigned exclusively to tau, TDP-43, or BMAA.
  role: effector
  mechanism_confidence: ESTABLISHED
  biological_scale: TISSUE
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  locations:
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperreflexia and spinal muscular atrophy, developing mainly in the distal
      extremities, are frequently observed.
    explanation: The upper- and lower-motor-neuron signs support motor-system degeneration in Guam PDC.
  downstream:
  - target: Motor Neuron Disease (ALS)
    description: Motor-system degeneration produces the ALS-predominant component of the disease spectrum.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:10525998
      reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These mixed-syndrome patients can be seen as clear support for the view
        that Guam ALS and PDC constitute a single mixed disease entity with a
        spectrum of clinical expression.
      explanation: Directly places ALS within the Guam mixed-disease spectrum.
  - target: Hyperreflexia
    description: Upper-motor-neuron and pyramidal-system dysfunction produces hyperactive stretch reflexes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Upper-motor-neuron and pyramidal-tract dysfunction
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:10525998
      reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Hyperreflexia and spinal muscular atrophy, developing mainly in the distal
        extremities, are frequently observed.
      explanation: Directly documents hyperreflexia within the motor-neuron disease spectrum.
  - target: Distal Amyotrophy
    description: Lower-motor-neuron denervation produces distal spinal muscular atrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Lower-motor-neuron denervation and skeletal-muscle wasting
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:10525998
      reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Hyperreflexia and spinal muscular atrophy, developing mainly in the distal
        extremities, are frequently observed.
      explanation: Directly documents distally predominant spinal muscular atrophy.
- name: Nigrostriatal Dopaminergic Dysfunction
  description: >-
    PET demonstrates reduced presynaptic striatal fluorodopa uptake in Guam PDC,
    with intermediate reductions in Guam ALS and reductions in some clinically
    normal Guamanians. This is a living-subject readout of nigrostriatal injury,
    not a disease-specific diagnostic signature.
  role: effector
  mechanism_confidence: ESTABLISHED
  biological_scale: TISSUE
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  evidence:
  - reference: PMID:2375693
    reference_title: Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The nigrostriatal lesions in the subjects with amyotrophic lateral sclerosis
      and the Guamanian normal subjects are examples of subclinical neuronal damage
      demonstrable in living subjects with positron emission tomography.
    explanation: Directly establishes a living-subject nigrostriatal lesion extending beyond clinically manifest parkinsonism.
  downstream:
  - target: Atypical Parkinsonism
    description: Presynaptic nigrostriatal dopaminergic dysfunction produces the parkinsonian component.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:2375693
      reference_title: Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The parkinsonian subjects all had significantly reduced striatal 18F-6-fluorodopa uptake.
      explanation: Directly links the presynaptic dopaminergic lesion to Guam parkinsonism.
  - target: Rigidity
    description: Dopaminergic and extrapyramidal dysfunction contributes to marked rigidity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Striatal dopamine deficiency and extrapyramidal motor-circuit dysfunction
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:10525998
      reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In PDC, rigidity is so marked that postural deformities such as a generally
        flexed posture become rather prominent.
      explanation: Directly documents marked rigidity in the Guam PDC form.
  - target: Gait Disturbance
    description: Bradykinesia, rigidity, and impaired postural reflexes disrupt gait.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Bradykinesia, rigidity, and impaired postural reflexes
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:10525998
      reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Gait disturbances are a common initial symptom.
      explanation: Directly documents gait disturbance as an initial Guam PDC manifestation.
- name: Dementia-Associated Neuronal Dysfunction
  description: >-
    Progressive cognitive deterioration accompanies the Guam PDC form. The entry
    conservatively represents a neuronal-system outcome without assigning a
    specific cortical circuit or asserting that one protein lesion alone causes it.
  role: effector
  mechanism_confidence: ESTABLISHED
  biological_scale: TISSUE
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dementia in PDC is characterized by a progressive dulling of all
      intellectual faculties, recent memory deﬁcits, disorien- tation in time,
      place and then person, as well as personality and behavioral changes.
    explanation: Directly describes progressive cognitive-system dysfunction in Guam PDC.
  downstream:
  - target: Dementia
    description: Progressive neuronal dysfunction manifests clinically as dementia.
    causal_link_type: DIRECT
    hypothesis_groups:
    - canonical_guam_multiple_proteinopathy
    evidence:
    - reference: PMID:10525998
      reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Important diagnostic indicators of the illness include rigido-akinetic type
        Parkinsonism and severe dementia.
      explanation: Directly supports dementia as a defining clinical manifestation.
- name: L-BMAA Neurotoxic Exposure
  description: >-
    Dietary L-BMAA is retained as the trigger of an alternative cycad-toxin
    hypothesis. Guam ecosystem measurements and experimental systems make the
    route biologically plausible, but neither those observations nor this node
    establish that human exposure caused Guam ALS-PDC.
  role: trigger
  mechanism_confidence: HYPOTHETICAL
  biological_scale: ORGANISM
  chemical_entities:
  - preferred_term: L-BMAA
    term:
      id: CHEBI:73169
      label: L-BMAA
  evidence:
  - reference: PMID:14612559
    reference_title: Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The biomagnification of BMAA through the Guam ecosystem fits a classic
      triangle of increasing concentrations of toxic compounds up the food chain.
    explanation: Supports environmental bioaccumulation but does not establish a causal human exposure dose.
  - reference: PMID:28598725
    reference_title: A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      The relationship of BMAA and ALS/PDC has never been proven, and the
      neurotoxic effects of BMAA seen in animals have only been noted after large
      doses that would involve unrealistic human exposures.
    explanation: The critical review directly limits causal extrapolation from experimental exposure to Guam disease.
  downstream:
  - target: AMPA/Kainate Receptor Overactivation and Calcium Overload
    description: In spinal-cord cultures, BMAA activates AMPA/kainate receptors and preferentially raises motor-neuron intracellular calcium.
    causal_link_type: DIRECT
    hypothesis_groups:
    - cycad_bmaa_neurotoxicity_model
    evidence:
    - reference: PMID:16764863
      reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The glutamate receptor antagonist NBQX prevented BMAA-induced death,
        implicating excitotoxic activation of AMPA/kainate receptors.
      explanation: Pharmacologic blockade directly supports receptor-dependent toxicity in culture.
  - target: Tau-Dominant Neurofibrillary Pathology
    description: Chronic dietary BMAA produced tau tangles in a vervet model; translation to human Guam disease remains unproven.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - cycad_bmaa_neurotoxicity_model
    evidence:
    - reference: PMID:26791617
      reference_title: Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Vervets (Chlorocebus sabaeus) fed for 140 days with BMAA-dosed fruit
        developed NFT and sparse β-amyloid deposits in the brain.
      explanation: Model-organism evidence supports a possible route to tau pathology without proving the route in humans.
- name: AMPA/Kainate Receptor Overactivation and Calcium Overload
  conforms_to: "glutamate_excitotoxicity#Glutamate Receptor Overactivation and Calcium Overload"
  description: >-
    In dissociated spinal-cord cultures, L-BMAA-dependent AMPA/kainate receptor
    activation produces preferential intracellular calcium rises in motor
    neurons. This is an in-vitro mechanism within the alternative BMAA model.
  role: central_effector
  mechanism_confidence: PROVISIONAL
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  biological_processes:
  - preferred_term: calcium ion transmembrane transport
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
    modifier: INCREASED
  evidence:
  - reference: PMID:16764863
    reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Ca(2+)](i) rises and selective reactive oxygen species (ROS) generation in
      MNs with minimal effect on other spinal neurons.
    explanation: Directly supports preferential motor-neuron calcium and ROS responses in culture.
  downstream:
  - target: Oxidative Stress in Vulnerable Motor Neurons
    description: BMAA-induced calcium stress accompanies selective ROS generation in cultured motor neurons.
    causal_link_type: DIRECT
    hypothesis_groups:
    - cycad_bmaa_neurotoxicity_model
    evidence:
    - reference: PMID:16764863
      reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Ca(2+)](i) rises and selective reactive oxygen species (ROS) generation
        in MNs with minimal effect on other spinal neurons.
      explanation: Directly links the receptor-associated response to selective ROS generation in vitro.
  - target: Excitotoxic Motor Neuron Death
    description: AMPA/kainate receptor activation is required for BMAA-induced death in cultured motor neurons.
    causal_link_type: DIRECT
    hypothesis_groups:
    - cycad_bmaa_neurotoxicity_model
    evidence:
    - reference: PMID:16764863
      reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The glutamate receptor antagonist NBQX prevented BMAA-induced death,
        implicating excitotoxic activation of AMPA/kainate receptors.
      explanation: Receptor antagonism prevented the experimental cell-death outcome.
- name: Oxidative Stress in Vulnerable Motor Neurons
  description: >-
    Selective ROS generation occurs in cultured motor neurons exposed to BMAA.
    The evidence is experimental and does not demonstrate oxidative stress as a
    measured lesion in Guam patients.
  role: downstream_effector
  mechanism_confidence: PROVISIONAL
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:16764863
    reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Ca(2+)](i) rises and selective reactive oxygen species (ROS) generation in
      MNs with minimal effect on other spinal neurons.
    explanation: Direct evidence of selective ROS generation in cultured motor neurons.
  downstream:
  - target: Excitotoxic Motor Neuron Death
    description: Selective ROS generation accompanies BMAA-induced motor-neuron loss, but the experiment does not fully isolate ROS as the sole mediator.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Oxidative injury and loss of cellular redox homeostasis
    hypothesis_groups:
    - cycad_bmaa_neurotoxicity_model
    evidence:
    - reference: PMID:16764863
      reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        BMAA was found to induce selective motor neuron (MN) loss in dissociated
        mixed spinal cord cultures at concentrations ( approximately 30 muM)
        significantly lower than those previously found to induce widespread
        neuronal degeneration.
      explanation: Establishes the downstream loss in the same culture system while the ROS-specific mediation remains inferential.
- name: Excitotoxic Motor Neuron Death
  description: >-
    BMAA produces selective motor-neuron loss in mixed spinal-cord cultures.
    This experimentally observed cell-death node belongs only to the alternative
    BMAA hypothesis and is not treated as proof of the lesion in human Guam tissue.
  role: downstream_effector
  mechanism_confidence: PROVISIONAL
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  evidence:
  - reference: PMID:16764863
    reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      BMAA was found to induce selective motor neuron (MN) loss in dissociated
      mixed spinal cord cultures at concentrations ( approximately 30 muM)
      significantly lower than those previously found to induce widespread
      neuronal degeneration.
    explanation: Directly demonstrates selective motor-neuron loss in an in-vitro spinal-cord system.
  downstream:
  - target: Motor Neuron Degeneration
    description: Experimental motor-neuron death is a possible route to the human motor-system lesion, but cross-system translation is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - cycad_bmaa_neurotoxicity_model
    evidence:
    - reference: PMID:16764863
      reference_title: BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Present findings support the hypothesis that BMAA may contribute to the selective MN loss in ALS/PDC.
      explanation: The authors frame the clinical translation as a hypothesis rather than human causal evidence.
phenotypes:
- category: Neurological
  name: Atypical Parkinsonism
  description: >-
    A severe rigido-akinetic parkinsonian syndrome is a defining component of
    Guam PDC and may occur with dementia or motor-neuron manifestations.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Important diagnostic indicators of the illness include rigido-akinetic type
      Parkinsonism and severe dementia.
    explanation: Directly identifies the rigido-akinetic parkinsonian component of Guam PDC.
- category: Neurological
  name: Dementia
  description: >-
    Progressive global cognitive decline, memory impairment, disorientation,
    and behavioral or personality change characterize the dementia component.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dementia in PDC is characterized by a progressive dulling of all
      intellectual faculties, recent memory deﬁcits, disorien- tation in time,
      place and then person, as well as personality and behavioral changes.
    explanation: Directly describes progressive dementia in Guam PDC.
- category: Neurological
  name: Motor Neuron Disease (ALS)
  description: >-
    An ALS-predominant form is part of the Guam ALS-PDC spectrum; the PDC form
    may also show upper- and lower-motor-neuron involvement.
  phenotype_term:
    preferred_term: Amyotrophic lateral sclerosis
    term:
      id: HP:0007354
      label: Amyotrophic lateral sclerosis
  evidence:
  - reference: PMID:18843496
    reference_title: Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions
      involving multiple nerve fiber tracts occurred in both the ALS and PDC types,
      reinforcing the concept that these forms are part of the same disorder.
    explanation: Supports ALS and PDC as clinical-pathologic forms of the same Guam disorder.
- category: Neurological
  name: Rigidity
  description: >-
    Marked axial and limb rigidity contributes to a flexed posture and severe
    movement impairment in the PDC-predominant form.
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In PDC, rigidity is so marked that postural deformities such as a generally
      flexed posture become rather prominent.
    explanation: Directly documents marked rigidity in Guam PDC.
- category: Neurological
  name: Bradykinesia
  subtype: PDC-predominant
  description: Bradykinesia is present in most patients with the PDC-predominant form.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Most PDC patients show bradykinesia and rigidity similar to what is seen with Parkinson’s disease, but more marked.
    explanation: Directly supports bradykinesia in most PDC patients without extending the frequency to other forms.
- category: Neurological
  name: Dysarthria
  subtype: PDC-predominant
  description: Dysarthria occurs in the PDC-predominant form as bulbar function deteriorates.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Dysarthria and dysphagia occur in all PDC patients, usually as a result of both extrapyramidal and cortico-bulbar dysfunc- tion, compounded by advancing dementia [2].
    explanation: Directly supports dysarthria in the reviewed PDC series without extending the claim to ALS-predominant disease.
- category: Neurological
  name: Dysphagia
  subtype: PDC-predominant
  description: Dysphagia occurs in the PDC-predominant form as bulbar function deteriorates.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Dysarthria and dysphagia occur in all PDC patients, usually as a result of both extrapyramidal and cortico-bulbar dysfunc- tion, compounded by advancing dementia [2].
    explanation: Directly supports dysphagia in the reviewed PDC series without extending the claim to ALS-predominant disease.
- category: Neurological
  name: Mask-like Facies
  subtype: PDC-predominant
  description: Mask-like facies with reduced blinking occurs in the PDC-predominant form.
  phenotype_term:
    preferred_term: Mask-like facies
    term:
      id: HP:0000298
      label: Mask-like facies
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Masked, oily faces and reduced blinking develop in all PDC patients.
    explanation: Directly supports mask-like facies in PDC without extending the frequency to other forms.
- category: Neurological
  name: Gait Disturbance
  description: >-
    Gait disturbance is often an initial symptom and reflects bradykinesia,
    rigidity, and impaired postural reflexes.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This gait disturbance is due to bradykinesia, rigidity and impaired
      postural reﬂexes.
    explanation: Directly describes the clinical intermediates underlying gait disturbance.
- category: Neurological
  name: Hyperreflexia
  description: Hyperreflexia reflects pyramidal or upper-motor-neuron involvement in the Guam disease spectrum.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperreflexia and spinal muscular atrophy, developing mainly in the distal
      extremities, are frequently observed.
    explanation: Directly documents hyperreflexia in Guam PDC.
- category: Musculoskeletal
  name: Distal Amyotrophy
  description: Distal spinal muscular atrophy reflects lower-motor-neuron and denervation involvement.
  phenotype_term:
    preferred_term: Distal amyotrophy
    term:
      id: HP:0003693
      label: Distal amyotrophy
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperreflexia and spinal muscular atrophy, developing mainly in the distal
      extremities, are frequently observed.
    explanation: Directly documents distal muscular atrophy in Guam PDC.
- category: Neurological
  name: Abnormal Eye Movement
  description: >-
    A 37-patient Lytico-Bodig series found supranuclear eye or lid motor
    abnormalities in every examined patient, with heterogeneous pursuit, gaze,
    vestibulo-ocular, convergence, fixation, nystagmus, and eyelid findings. A
    separate clinical review described ocular motility as usually intact and
    vertical gaze impairment as rare, so population frequency remains uncertain.
  review_notes: >-
    Deliberately left outside the causal pathograph because the series establishes
    the examination finding but not which Guam ALS-PDC mechanism produces it. The
    all-37 examination series conflicts directly with the lower frequency described
    in PMID:10525998; neither estimate is generalized beyond its source.
  phenotype_term:
    preferred_term: Abnormality of eye movement
    term:
      id: HP:0000496
      label: Abnormality of eye movement
  evidence:
  - reference: PMID:3194062
    reference_title: Supranuclear disturbances of ocular motility in Lytico-Bodig.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found abnormal supranuclear ocular or lid motility in all of 37 patients
      with Lytico-Bodig (amyotrophic lateral sclerosis/parkinsonism-dementia
      complex).
    explanation: >-
      Supports the phenotype in the examined series while preserving the cohort
      denominator and avoiding a universal disease-level frequency claim.
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ocular motility usually remains intact, although in rare cases vertical gaze,
      especially upward, ultimately becomes impaired.
    explanation: >-
      Supports rare vertical-gaze impairment while conflicting with the all-patient
      frequency reported in the separate 37-patient ocular-motor series.
- category: Ophthalmologic
  name: Linear Retinal Pigment Epitheliopathy
  description: >-
    Linear retinal pigment epitheliopathy was associated with prevalent Guam
    ALS-PDC and predicted incident neurologic disease in a longitudinal subset.
    It is a risk marker rather than a specific or confirmatory diagnostic finding.
  phenotype_term:
    preferred_term: Linear retinal pigment epitheliopathy
  review_notes: >-
    No exact HP term for the linear Guam lesion was identified; a broader retinal
    pigment epithelial mottling or atrophy term was not substituted.
  evidence:
  - reference: PMID:26153661
    reference_title: A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prospectively, 15 of 50 cases with epitheliopathy developed amyotrophic
      lateral sclerosis/parkinsonism-dementia complex, compared to 4 of 189 cases
      without epitheliopathy (age- and sex-adjusted hazard ratio: 13.1; 95% CI:
      4.0-43.1; P < 0.0001).
    explanation: >-
      Directly supports prospective association in the reported cohort without
      asserting etiologic causation or diagnostic specificity.
biochemical: []
histopathology:
- name: Widespread Mixed 3R/4R Tau Neurofibrillary Tangles
  description: >-
    Widespread neurofibrillary tangles expressing both 3R and 4R tau are the
    most prominent postmortem hallmark. The finding is characteristic but was
    not reported as pathognomonic relative to other degenerative disorders.
  diagnostic: false
  evidence:
  - reference: PMID:21527311
    reference_title: "The ALS/PDC syndrome of Guam: potential biomarkers for an enigmatic disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The most prominent pathological hallmark is the widespread occurrence of
      neurofibrillary tangles which express the same balance of 3R and 4R tau
      that is found in Alzheimer disease.
    explanation: Directly establishes the principal mixed-isoform tau finding.
- name: CTE-Fold Tau Filaments
  description: >-
    Cryo-electron microscopy identified CTE-fold tau filaments in the sampled
    Guam cerebral cortex and spinal cord. Structural similarity does not make
    Guam ALS-PDC equivalent to chronic traumatic encephalopathy and does not by
    itself identify an exogenous cause.
  diagnostic: false
  evidence:
  - reference: PMID:38100415
    reference_title: Tau filaments from amyotrophic lateral sclerosis/parkinsonism-dementia complex adopt the CTE fold.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Tau filaments had the chronic traumatic encephalopathy (CTE) fold, with
      variable amounts of Type I and Type II filaments.
    explanation: >-
      Supports the structural fold in the sampled postmortem material without
      adopting the authors' separate etiologic inference.
- name: TDP-43-Positive Neuronal and Glial Inclusions
  description: >-
    TDP-43-positive inclusions occur in neurons, oligodendroglia, and astrocytes
    across both ALS and PDC forms; the cited source does not specify cytoplasmic
    localization in its available text.
  diagnostic: false
  evidence:
  - reference: PMID:18843496
    reference_title: Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tau and TDP-43 positive neuronal, oligodendroglial and astrocytic inclusions
      involving multiple nerve fiber tracts occurred in both the ALS and PDC types,
      reinforcing the concept that these forms are part of the same disorder.
    explanation: Direct autopsy evidence for TDP-43-positive neuronal and glial inclusions.
  - reference: PMID:17713769
    reference_title: Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      G-PDC was associated with cortical TDP-43 positive dystrophic neurites and
      neuronal and glial inclusions in gray and/or white matter.
    explanation: >-
      Directly supports cortical TDP-43 neurites and inclusions in Guam PDC.
- name: Variable Amyloid-Beta Plaques and Alpha-Synuclein Lewy Bodies
  description: >-
    Sparse Aβ plaques and occasional α-synuclein Lewy bodies are variable
    co-pathologies. Histologic α-synuclein deposits are distinct from
    α-synuclein prion activity, which was not detected in the sampled cohorts.
  diagnostic: false
  evidence:
  - reference: PMID:36952379
    reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC)
      of Guam is an endemic neurodegenerative disease that features widespread
      tau tangles, occasional α-synuclein Lewy bodies, and sparse β-amyloid (Aβ)
      plaques distributed in the central nervous system.
    explanation: Directly establishes occasional Lewy bodies and sparse amyloid plaques.
  - reference: PMID:36952379
    reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In ALS-PDC brain samples, we detected high titers of tau and Aβ prions, but
      we did not detect α-synuclein prions in either cohort.
    explanation: Prevents conflation of occasional Lewy bodies with detectable α-synuclein prion activity.
imaging_findings:
- name: Reduced Striatal 18F-6-Fluorodopa Uptake on PET
  modality: PET
  imaging_finding_term:
    preferred_term: reduced striatal 18F-6-fluorodopa uptake
  description: >-
    PET demonstrates reduced striatal presynaptic fluorodopa uptake in Guam
    parkinsonism. Intermediate or reduced uptake also occurred in ALS and some
    clinically normal Guamanians, so the finding is not disease-specific.
  located_in:
    preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  diagnostic: false
  notes: >-
    A functional correlate of nigrostriatal damage, not a confirmatory biomarker;
    subclinical abnormalities occurred outside clinically parkinsonian subjects.
  evidence:
  - reference: PMID:2375693
    reference_title: Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The parkinsonian subjects all had significantly reduced striatal
      18F-6-fluorodopa uptake. The group with amyotrophic lateral sclerosis had
      significantly reduced uptake that was intermediate between that of the
      control group and the parkinsonian group. Two Guamanian normal subjects
      had reduced striatal 18F-6-fluorodopa uptake.
    explanation: Directly documents the finding and its limited specificity.
genetic:
- name: TRPM7
  gene_term:
    preferred_term: TRPM7
    term:
      id: hgnc:17994
      label: TRPM7
  association: Candidate T1482I gene-environment susceptibility allele in a proposed low-calcium, low-magnesium context.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  review_notes: >-
    Candidate association only. It is not represented as a causative Mendelian
    allele, and no supported causal path from TRPM7 to the observed neuropathology
    is asserted.
  evidence:
  - reference: PMID:16051700
    reference_title: A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found a TRPM7 variant in a subset of ALS-G and PD-G patients that
      produces a protein with a missense mutation, T1482I.
    explanation: Supports a variant in a subset rather than a disease-defining causal gene.
  - reference: PMID:16051700
    reference_title: A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      However, heterologously expressed T1482I TRPM7 produces functional channels
      that show an increased sensitivity to inhibition by intracellular Mg2+.
    explanation: Directly supports the altered channel property in a heterologous system.
- name: Chromosome 12p D12S1617 susceptibility locus
  association: >-
    Candidate linkage and allelic-association signal from a large, genetically
    isolated Guam sample; not a resolved causal gene or independently replicated
    disease mechanism.
  relationship_type: SUSCEPTIBILITY
  review_notes: >-
    Kept at locus level because the study did not identify a causal gene. The
    complex pedigree and isolate structure limit generalization.
  evidence:
  - reference: PMID:19567404
    reference_title: "Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      D12S1617 on 12p gave the strongest evidence of linkage (maximum LOD score,
      Z(max) = 4.03) in our initial scan, with additional support in the complete
      case-control sample in the form of evidence of allelic association at this
      marker and another nearby marker.
    explanation: >-
      Supports a candidate linkage/association locus in the sampled isolate, not
      a causal variant or gene.
- name: MAPT-region susceptibility signal
  gene_term:
    preferred_term: MAPT
    term:
      id: hgnc:6893
      label: MAPT
  association: Supportive, non-causal linkage evidence at the chromosome 17 MAPT region.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  review_notes: >-
    The cited genome scan calls the evidence supportive rather than significant;
    this entry does not equate the signal with a causative MAPT allele.
  evidence:
  - reference: PMID:19567404
    reference_title: "Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found significant evidence for two regions with novel ALS/PDC loci on
      chromosome 12 and supportive evidence for the involvement of the MAPT region
      on chromosome 17.
    explanation: >-
      Directly supports only a regional susceptibility signal, with no causal
      MAPT variant established.
- name: C9orf72 repeat-expansion hypothesis
  gene_term:
    preferred_term: C9orf72
    term:
      id: hgnc:28337
      label: C9orf72
  presence: Not detected as a cause in the studied Chamorro series
  association: Pathogenic repeat expansion tested and refuted as a cause of Chamorro Guam ALS-PDC.
  relationship_type: DISPUTED
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:23588498
    reference_title: C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All Chamorro participants with ALS and PDC and control subjects had normal
      repeats, ranging from 2 to 17 copies.
    explanation: >-
      Refutes pathogenic C9orf72 repeat expansion in the 24 ALS cases, 22 PDC
      cases, and 43 controls studied; it is not a claim about every possible case.
- name: LRRK2 mutation hypothesis
  gene_term:
    preferred_term: LRRK2
    term:
      id: hgnc:18618
      label: LRRK2
  presence: No pathogenic mutation found in the studied Guam series
  association: Pathogenic point mutations tested and refuted as a cause in the sampled population.
  relationship_type: DISPUTED
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:23588498
    reference_title: C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: No pathogenic LRRK2 mutations were found.
    explanation: >-
      Refutes pathogenic LRRK2 point mutations in the study series without
      asserting exhaustive exclusion of every possible LRRK2 variant.
environmental:
- name: Cycad-Ecosystem L-BMAA Ingestion (Candidate)
  description: >-
    Ingestion of L-BMAA through cycad-associated foods, including proposed
    trophic transfer through flying foxes, is a historically important exposure
    hypothesis. Ecosystem biomagnification was reported, but a causal human dose
    and a causal relationship to Guam ALS-PDC have not been established.
  exposure_term:
    preferred_term: L-BMAA dietary exposure
    term:
      id: ECTO:0000231
      label: exposure to chemical
  chemicals:
  - L-BMAA
  effect: Candidate neurotoxic trigger; human causality remains unresolved.
  review_notes: >-
    Retained only as the environmental exposure corresponding to the alternative
    BMAA hypothesis. The ingestion route is ExO:0000056 (ingestion), recorded
    here in free text because that route term is outside the ExposureTerm schema
    root and therefore cannot be bound in exposure_term.
  evidence:
  - reference: PMID:14612559
    reference_title: Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Flying foxes are a prized food item of the indigenous Chamorro people who
      boil them in coconut cream and eat them whole.
    explanation: Supports a proposed ingestion route but not a causal or sufficient human exposure dose.
  - reference: PMID:28598725
    reference_title: A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      The review concludes that the hypothesis of a causal BMAA neurodegenerative
      disease relationship is not supported by existing data.
    explanation: Directly records the critical review's conclusion against a demonstrated causal relationship.
  - reference: PMID:36952379
    reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Extensive studies of genetic or environmental factors have failed to
      identify a cause of ALS-PDC.
    explanation: Confirms that environmental causation remains unresolved.
diagnosis:
- name: Neurological Physical Examination
  description: >-
    Examination identifies the combined rigido-akinetic, pyramidal,
    lower-motor-neuron, gait, and cognitive syndrome and helps assign a clinical
    form. The findings are syndromic rather than etiologically confirmatory.
  diagnosis_term:
    preferred_term: physical examination
    term:
      id: NCIT:C20989
      label: Physical Examination
  results: Rigido-akinetic parkinsonism, rigidity, gait disturbance, hyperreflexia, distal amyotrophy, or an ALS syndrome in the appropriate Guam context.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Important diagnostic indicators of the illness include rigido-akinetic type
      Parkinsonism and severe dementia.
    explanation: Establishes key examination indicators of the PDC-predominant form.
- name: Cognitive Assessment
  description: >-
    Cognitive assessment characterizes the progressive global dementia component
    but does not distinguish Guam ALS-PDC from other neurodegenerative diseases.
  diagnosis_term:
    preferred_term: cognitive assessment
    term:
      id: NCIT:C165543
      label: Neuropsychological Assessment
  results: Progressive global intellectual decline with memory, orientation, personality, and behavioral change.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dementia in PDC is characterized by a progressive dulling of all
      intellectual faculties, recent memory deﬁcits, disorien- tation in time,
      place and then person, as well as personality and behavioral changes.
    explanation: Supports the cognitive domains requiring assessment without validating a specific test instrument.
- name: Striatal Fluorodopa PET
  description: >-
    18F-6-fluorodopa PET can demonstrate presynaptic nigrostriatal dysfunction,
    but reduced uptake also occurred in Guam ALS and clinically normal Guam
    subjects and therefore is not confirmatory.
  diagnosis_term:
    preferred_term: positron emission tomography procedure
    term:
      id: NCIT:C17007
      label: Positron Emission Tomography
  results: Reduced striatal 18F-6-fluorodopa uptake, with the strongest reduction in clinically parkinsonian subjects.
  evidence:
  - reference: PMID:2375693
    reference_title: Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The nigrostriatal lesions in the subjects with amyotrophic lateral sclerosis
      and the Guamanian normal subjects are examples of subclinical neuronal damage
      demonstrable in living subjects with positron emission tomography.
    explanation: Supports PET detection of living-subject neuronal damage while demonstrating limited diagnostic specificity.
- name: Postmortem Neuropathologic Examination
  description: >-
    A 2011 review reported that Guam and Kii ALS/PDC could then be confirmed only
    by postmortem examination. This is retained as historical diagnostic context,
    not a timeless claim that no premortem biomarker can ever be available.
  diagnosis_term:
    preferred_term: autopsy procedure
    term:
      id: NCIT:C25153
      label: Autopsy
  results: Widespread mixed 3R/4R tau neurofibrillary pathology with associated protein lesions in a compatible clinicogeographic syndrome.
  evidence:
  - reference: PMID:21527311
    reference_title: "The ALS/PDC syndrome of Guam: potential biomarkers for an enigmatic disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      At present, ALS/PDC of Guam and the Kii Peninsula can be confirmed only by
      postmortem examination.
    explanation: Records the review's 2011 confirmation standard with explicit temporal scope.
- name: Ocular Motor Examination
  description: >-
    Examination can identify supranuclear ocular and eyelid motor abnormalities,
    but the evidence is a single 37-patient series and does not validate a
    stand-alone diagnostic test.
  diagnosis_term:
    preferred_term: eye examination
    term:
      id: NCIT:C38060
      label: Eye Examination
  results: Heterogeneous supranuclear ocular or lid motor abnormalities.
  evidence:
  - reference: PMID:3194062
    reference_title: Supranuclear disturbances of ocular motility in Lytico-Bodig.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found abnormal supranuclear ocular or lid motility in all of 37 patients
      with Lytico-Bodig (amyotrophic lateral sclerosis/parkinsonism-dementia
      complex).
    explanation: >-
      Supports examination yield in the reported series, not specificity or a
      validated diagnostic threshold.
- name: Retinal Examination for Linear Pigment Epitheliopathy
  description: >-
    Retinal examination may identify the associated linear pigment epitheliopathy.
    Its prospective association makes it a candidate risk marker, not a
    confirmatory test for ALS-PDC.
  diagnosis_term:
    preferred_term: eye examination
    term:
      id: NCIT:C38060
      label: Eye Examination
  results: Presence or absence of linear retinal pigment epitheliopathy.
  evidence:
  - reference: PMID:26153661
    reference_title: A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The epitheliopathy was present in 59.7% (117 of 196) patients with
      amyotrophic lateral sclerosis/parkinsonism-dementia complex, but in only
      24.7% (178 of 722) of subjects who were neurologically asymptomatic
    explanation: >-
      Supports association and incomplete sensitivity/specificity, which is why
      the examination is not represented as confirmatory.
differential_diagnoses:
- name: Parkinson disease
  disease_term:
    preferred_term: Parkinson disease
    term:
      id: MONDO:0005180
      label: Parkinson disease
  description: >-
    Parkinson disease overlaps with the bradykinetic-rigid presentation of Guam
    PDC. Dementia, motor-neuron signs, rapid progression, and the Mariana
    clinicogeographic context favor ALS-PDC, but no single premortem discriminator
    has been validated.
  distinguishing_features:
  - Guam PDC progresses relatively rapidly compared with Parkinson disease.
  - Coexisting dementia and upper- or lower-motor-neuron signs favor the Guam spectrum.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PDC must be diagnosed so as to differentiate it from other disorders such as
      Parkinson’s disease, Alzheimer’s disease, progressive supranuclear palsy
      (PSP),
    explanation: Directly identifies Parkinson disease as a clinical differential.
- name: Alzheimer disease
  disease_term:
    preferred_term: Alzheimer disease
    term:
      id: MONDO:0004975
      label: Alzheimer disease
  description: >-
    Alzheimer disease overlaps through dementia, tau tangles, and variable Aβ
    pathology. Guam ALS-PDC adds a characteristic motor spectrum and a molecular
    tau/Aβ-prion signature that differed from sporadic Alzheimer disease in one
    postmortem bioassay cohort.
  distinguishing_features:
  - Guam ALS-PDC may include atypical parkinsonism and upper- or lower-motor-neuron disease.
  - Postmortem molecular signature differed from sporadic Alzheimer disease in the cited study.
  evidence:
  - reference: PMID:36952379
    reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Applying partial least squares regression to all biochemical and prion
      infectivity measurements, we demonstrated that the ALS-PDC cohort has a
      unique molecular signature distinguishable from AD.
    explanation: >-
      Supports a postmortem biochemical distinction in the sampled cohorts, not
      a validated premortem differential test.
- name: Progressive supranuclear palsy
  disease_term:
    preferred_term: progressive supranuclear palsy
    term:
      id: MONDO:0019037
      label: progressive supranuclear palsy
  description: >-
    Progressive supranuclear palsy overlaps through atypical parkinsonism,
    rigidity, gait impairment, supranuclear ocular motor dysfunction, and
    tauopathy. Guam ALS-PDC may additionally show dementia and motor-neuron
    involvement in its characteristic geographic and familial setting.
  distinguishing_features:
  - Motor-neuron disease within the ALS-PDC spectrum is not a defining PSP feature.
  - Historical Guam or Rota ancestry and epidemiologic context support ALS-PDC but are not independently diagnostic.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PDC must be diagnosed so as to differentiate it from other disorders such as
      Parkinson’s disease, Alzheimer’s disease, progressive supranuclear palsy
      (PSP),
    explanation: Directly identifies progressive supranuclear palsy as a clinical differential.
- name: Corticobasal degeneration
  disease_term:
    preferred_term: corticobasal degeneration disorder
    term:
      id: MONDO:0022308
      label: corticobasal degeneration disorder
  description: >-
    Corticobasal degeneration overlaps through atypical parkinsonism, cortical
    dysfunction, and tauopathy. Motor-neuron involvement and the Mariana
    clinicogeographic context may support Guam ALS-PDC but are not independently
    diagnostic.
  distinguishing_features:
  - Motor-neuron disease within the ALS-PDC spectrum is not a defining feature of corticobasal degeneration.
  - Historical Guam or Rota ancestry and epidemiologic context support ALS-PDC but are not independently diagnostic.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: progressive supranuclear palsy (PSP), corticobasal degenera- tion (CBD),
    explanation: Directly identifies corticobasal degeneration as a clinical differential.
- name: Dementia with Lewy bodies
  disease_term:
    preferred_term: Lewy body dementia
    term:
      id: MONDO:0007488
      label: Lewy body dementia
  description: >-
    Dementia with Lewy bodies overlaps through dementia and parkinsonism. The
    Guam spectrum may additionally include motor-neuron disease and a distinct
    historical Mariana epidemiologic context, but no single premortem discriminator
    has been validated.
  distinguishing_features:
  - Motor-neuron disease within the ALS-PDC spectrum is not a defining feature of Lewy body dementia.
  - Historical Guam or Rota ancestry and epidemiologic context support ALS-PDC but are not independently diagnostic.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: dementia with Lewy bodies (DLB).
    explanation: Directly identifies dementia with Lewy bodies as a clinical differential.
treatments:
- name: Levodopa for Early Parkinsonian Symptoms
  description: >-
    Some early-stage cases were reported to respond to levodopa. This is limited
    symptomatic evidence from a clinical overview, not evidence of durable benefit,
    disease modification, or efficacy across the ALS-PDC spectrum.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: L-dopa
      term:
        id: CHEBI:15765
        label: L-dopa
  target_phenotypes:
  - preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These cases occasionally present with the same clinical picture and response
      to levodopa in the early stage.
    explanation: >-
      Supports only occasional early symptomatic response; no controlled or
      disease-modifying treatment inference is made.
animal_models:
- species: Mouse (Mus musculus)
  background: Adult male CD-1 mice fed washed cycad-flour pellets
  category: Exposure model
  description: >-
    Washed cycad flour produced progressive motor and cognitive dysfunction and
    neurodegeneration in cortex, hippocampus, substantia nigra, olfactory bulb,
    and spinal cord. The study detected little of several previously proposed
    toxins and identified BSSG as the most toxic isolated component; this is a
    partial phenocopy, not proof of human causation.
  associated_phenotypes:
  - Progressive motor dysfunction
  - Cognitive dysfunction
  - Regionally distributed neurodegeneration
  evidence:
  - reference: PMID:12095162
    reference_title: Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Cycad-fed animals showed early evidence of progressive motor and cognitive
      dysfunctions. Neurodegeneration measured using TUNEL and caspase-3 labeling
      was found in neocortex, various hippocampal fields, substantia nigra,
      olfactory bulb, and spinal cord.
    explanation: Directly supports the model's behavioral and anatomic findings.
- species: Mouse (Mus musculus)
  background: Adult CD-1 and C57BL/6 mice chronically fed beta-sitosterol beta-D-glucoside (BSSG)
  category: Exposure model
  description: >-
    Dietary BSSG produced motor deficits, spinal motor-neuron loss, altered
    glutamate-transporter labeling, gliosis, and nigrostriatal changes. Different
    exposure schedules and backgrounds were used, and the model does not establish
    BSSG exposure or dose in human Guam ALS-PDC.
  associated_phenotypes:
  - Motor deficits
  - Spinal motor neuron loss
  - Nigrostriatal pathology
  evidence:
  - reference: PMID:18196479
    reference_title: Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      C57BL/6 mice fed BSSG-treated pellets for 10 weeks exhibited progressive
      loss of motor neurons in the lumbar spinal cord that continued to worsen
      even after the BSSG exposure ended.
    explanation: >-
      Directly supports progressive post-exposure motor-neuron loss in one of the
      two reported mouse backgrounds.
- species: Vervet monkey (Chlorocebus sabaeus)
  background: Chronic dietary BMAA exposure, with an L-serine co-treatment arm
  category: Exposure model
  description: >-
    Chronic BMAA exposure induced neurofibrillary tangles and amyloid deposits in
    vervets; L-serine reduced tangle density in the model. The experiment supports
    a preclinical hypothesis but does not establish comparable human exposure,
    therapeutic efficacy, or BMAA causation in Guam ALS-PDC.
  associated_phenotypes:
  - Neurofibrillary tangles
  - Amyloid deposits
  evidence:
  - reference: PMID:26791617
    reference_title: Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In replicated experiments, we found that chronic dietary exposure to a
      cyanobacterial toxin present in the traditional Chamorro diet,
      β-N-methylamino-l-alanine (BMAA), triggers the formation of both NFT and
      β-amyloid deposits similar in structure and density to those found in
      brain tissues of Chamorros who died with ALS/PDC.
    explanation: >-
      Supports neuropathologic similarity in a primate exposure model, not human
      disease causation.
experimental_models:
- name: Guam PDC patient-derived iPSC neural-cell resource
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: >-
    iPSCs from one PDC-affected Guamanian Chamorro woman and one age- and
    sex-matched healthy Chamorro resident of Saipan
  culture_system: >-
    iPSC-derived human neural progenitor cells, neurons, astrocyte progenitors,
    and mature astrocytes
  publication: PMID:41332773
  description: >-
    The resource provides patient-derived neural lineages for testing genetic and
    environmental hypotheses. The report establishes lineage generation and
    marker expression, not a disease-specific cellular phenotype, and the one-case,
    one-control design cannot separate disease effects from individual background.
  conditions:
  - Guam PDC patient-derived line
  - Unaffected Chamorro comparison line
  evidence:
  - reference: PMID:41332773
    reference_title: Development of Patient-Derived Neuroprogenitor Cells (hNPCs), Neurons and Astrocytes to Explore the Etiology of Guam Parkinsonism-Dementia Complex (PDC).
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Development of these patient-derived iPSCs provides a human model for
      evaluating the role of environmental (e.g., cycad toxins) and genetic factors
      in ALS-PDC and possibly other related neurodegenerative diseases.
    explanation: >-
      Supports the system as a hypothesis-testing resource, not as a validated
      phenocopy of ALS-PDC.
  notes: Preprint indexed in PubMed; no disease-specific cellular abnormality was claimed in the available abstract.
datasets: []
clinical_trials: []
discussions:
- discussion_id: gap_guam_alspdc_etiology
  prompt: What initiates Guam ALS-PDC, and how do genetic susceptibility and historical environmental change interact?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Tau-Dominant Neurofibrillary Pathology
  - pathophysiology#TDP-43-Positive Cellular Inclusions
  rationale: >-
    Human studies establish a mixed proteinopathy and changing incidence, but no
    genetic variant, dietary toxin, mineral exposure, or other environmental factor
    has been shown to be necessary or sufficient. The rapid temporal change argues
    against a purely genetic cause without identifying the responsible exposure.
  evidence:
  - reference: PMID:36952379
    reference_title: Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Extensive studies of genetic or environmental factors have failed to
      identify a cause of ALS-PDC.
    explanation: Directly states the unresolved etiologic gap.
  - reference: PMID:12522022
    reference_title: "Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rapid decrease in incidence is not likely to be due to genetic factors.
    explanation: >-
      Constrains a purely genetic explanation but does not identify an alternative cause.
- discussion_id: gap_cycad_model_to_human_translation
  prompt: Do BMAA, sterol glucosides, or another cycad constituent reproduce the initiating human exposure and mechanism of Guam ALS-PDC?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#L-BMAA Neurotoxic Exposure
  - pathophysiology#AMPA/Kainate Receptor Overactivation and Calcium Overload
  rationale: >-
    Mouse and vervet exposure models reproduce selected motor, cognitive, tau,
    amyloid, or motor-neuron readouts, but exposure identity and dose in affected
    people remain unresolved. The sterol-glucoside and L-BMAA models must not be
    collapsed into one exposure, and partial phenocopy does not demonstrate human
    causation.
  evidence:
  - reference: PMID:12095162
    reference_title: Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: These data are consistent with a number of major features of ALS-PDC in humans.
    explanation: The authors claim consistency with selected features, not complete model fidelity.
  - reference: PMID:28598725
    reference_title: "A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans."
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      The review concludes that the hypothesis of a causal BMAA neurodegenerative
      disease relationship is not supported by existing data.
    explanation: Directly records the gap between experimental BMAA findings and demonstrated human causation.
- discussion_id: gap_premortem_case_definition_and_biomarkers
  prompt: Which premortem biomarker combination can distinguish Guam ALS-PDC from overlapping neurodegenerative disorders?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - diagnosis#Postmortem Neuropathologic Examination
  rationale: >-
    Clinical examination, ocular findings, retinal epitheliopathy, and fluorodopa
    PET are informative but individually nonspecific. No contemporary validated
    premortem case definition or biomarker panel was identified in the reviewed
    literature.
  evidence:
  - reference: PMID:21527311
    reference_title: "The ALS/PDC syndrome of Guam: potential biomarkers for an enigmatic disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      There are as yet no identified pathological features that will clearly
      distinguish the Guam or Kii ALS/PDC syndrome from other degenerative
      neurological disorders.
    explanation: Directly supports the differential-diagnostic biomarker gap as assessed in 2011.
- discussion_id: gap_disease_modifying_treatment_and_trials
  prompt: Which interventions alter progression or survival in Guam ALS-PDC rather than only treating symptoms?
  kind: KNOWLEDGE_GAP
  status: OPEN
  rationale: >-
    The retained literature supports only occasional early levodopa response.
    Searches of the disease literature and ClinicalTrials.gov through 2026-08-04
    identified no Guam ALS-PDC-specific controlled therapeutic trial or established
    disease-modifying intervention. Trials in sporadic ALS, Parkinson disease, or
    progressive supranuclear palsy were not generalized to this complex.
  evidence:
  - reference: PMID:10525998
    reference_title: Parkinsonism-dementia complex on Guam - overview of clinical aspects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These cases occasionally present with the same clinical picture and response
      to levodopa in the early stage.
    explanation: >-
      Documents limited symptomatic response evidence while leaving progression,
      survival, and disease modification untested.

Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex

Ask OpenScientist

OpenScientist Report

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Diagnosis

Imaging Findings

Progression

Epidemiology

Differential Diagnoses

Experimental Models

Animal Models

Source YAML